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ABBREVIATIONS 
[I]50 concentration of the free inhibitor at 50% inhibition; also, 
concentration of the free inhibitor that reduces the TGLI of 
the probe:PK complex by half; also, the concentration the 
free inhibitor when 50% displacement has occurred 
ARC  biligand inhibitor or probe for protein kinases designed in 
Asko Uri´s research group at the University of Tartu 
ARC(Photo) ARC labelled with a fluorescent dye; photoluminescent 
probe, including ARC-Fluo and ARC-Lum(Fluo) probes 
ARC-Fluo  ARC-probe comprising a non-phosphorescent 
heteroaromatic fragment and a fluorescent dye 
ARC-Lum(Fluo) ARC-probe incorporating a phosphorescent heteroaromatic 
fragment and fluorescent dye; the probe possesses protein 
binding-induced photoluminescence with microsecond-
scale decay time 
ATB 4-(2-amino-1,3-thiazol-5-yl)benzoic acid 
CASP3 cysteine-aspartic acid protease caspase 3 
CHO cells Chinese hamster´s ovary cells 
CPP cell-penetrating peptide 
CREB cAMP response element-binding transcription factor 
GPCR G-protein coupled receptor 
FA fluorescence anisotropy 
FACS fluorescence-activated cell sorting 
FCS fluorescence correlation spectroscopy 
FI fluorescence intensity 
FRET Förster resonant energy transfer 
HeLa cells cervical cancer cells from Henrietta Lacks 
HTS high-throughput screening 
IC50  the total concentration of the inhibitor that reduces the 
TGLI of the probe:PK complex by half; also, the total 
concentration the inhibitor when 50% displacement has 
occurred 
Ida iminodiacetic acid 
Kd dissociation constant 
LoKd  limit of dissociation constant determination 
LoQ limit of quantification 
MA  maximum aggregation 
MALDI-TOF MS matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometer 
MDCK cells Madin-Darby canine kidney cells 
PC-3 cells human prostate cancer cells 
PK protein kinase 
PPC-1 cells human prostate cancer cells 
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RP-HPLC-FL reverse phase HPLC with a fluorescence detector 
RSD relative standard deviation 
SD standard deviation 
TBBz 4,5,6,7-tetrabromo-1H-benzimidazole 
TGLI time-gated measurement of luminescence intensity 
[luminescence intensity as measured in a defined period of 
time (time gate) after excitation of the luminophore with a 




Human cell is a complex biological system comprising a wide variety of mole-
cules, each playing its own role in the life cycle of a cell. Members of 540-
protein kinase (PK) superfamily catalyse the transfer of a small phosphoryl 
group from ATP to the target protein. This minor change in the chemical 
structure of the target protein affects most of the signalling pathways and, 
consequently, vital processes in the cell. 
Aberrant activity of PKs is the cause or result of several diseases: from 
cardiovascular diseases and different cancers to Alzheimer´s disease. Although 
PKs were considered to be potential drug targets already since their discovery in 
the 1950-s, the related research started to widen rapidly in the 1990-s and has 
not shown signs of extinction. During the years, the knowledge on the structure 
of PKs has supported the design of new inhibitors – regulators of the activity of 
PKs. Recently, the biligand approach of the design of inhibitors has gained 
attractiveness due to concurrent higher affinity and selectivity. 
Request for inhibitors regulating the activity of PKs and photoluminescent 
probes for studying signalling cascades mediated by PKs has driven the 
development of reliable analysis techniques. In this thesis, we introduce two 
methods. The first method is a binding assay for characterization of PK in-
hibitors possessing affinities in a wide range. The assay is based on the 
application of a non-metal PK binding-responsive photoluminescent ARC-
Lum(Fluo) probe with unique photoluminescent properties. The second, HPLC-
based method was used for determination of the concentration of potent 
biligand inhibitors and probes of PKs in cells. Unlike most cellular assays, the 
HPLC method described here affords the presentation of cellular uptake as 
concentration of the inhibitor in molar units that makes possible the comparison 
of analytical results for different cells and the data originating from different 
research groups. 
Besides the development of aforementioned analysis techniques, our other 
aim was the design of selective and potent biligand inhibitors for regulation and 
examination of signalling pathways that proceed with participation of CK2 or 
PKAc. Various strategies to enhance the cellular uptake of inhibitors were 
compared by the means of achieved intracellular concentration of inhibitor and 
intracellular availability. The inhibitory potency of the internalized biligand 
inhibitor was demonstrated by its effect on the phosphorylation levels of 
substrate proteins or on the signalling pathways related to the target kinase. The 
results support the applicability of biligand inhibitors for the development of 




2. LITERATURE OVERVIEW 
2.1. PROTEIN KINASES 
The discovery of a PK in 1954 revealed the feasibility of enzyme-catalysed 
phosphorylation of proteins in cells (Burnett and Kennedy 1954). The following 
identification of several PKs made possible the establishment of their 
participation in signal transduction pathways and disease mechanisms (Hunter 
2000). The transfer of a small structural fragment, the γ-phosphoryl group from 
ATP (or GTP in rare cases, e.g., CK2-catalysed reactions) to the substrate 
protein plays an important role in, e.g., the regulation of activity and trans-
localisation of the protein, and therefore, guidance of various cellular processes. 
The importance of PKs could be also illustrated by the incidence of 
corresponding genes: more than 500 genes encoding PKs (Manning et al. 2002) 
make up approximately 2.6% of the whole human genome. Here, we will 
concentrate on two remarkable kinases. CK2 – the earliest PK that was dis-
covered and the PK responsible for phosphorylating speculatively 20% (Salvi et 
al. 2009) among 13000 phosphorylateable proteins in human (Vlastaridis et al. 
2017). Second, protein kinase A (PKA) – PK of which the first three-
dimensional structure was determined (Knighton et al. 1991) and which has 
been also the most thoroughly studied PK since its discovery. Both of these PKs 
exist in a tetrameric complex and they are also ubiquitous, nevertheless, their 




PKA, also known as cAMP-dependent PK, belongs to the AGC group of PKs 
(Manning et al. 2002). AGC kinases are mostly basophilic enzymes as they 
catalyse phosphorylation of substrate proteins comprising basic amino acid 
residues (Arg and Lys) near the phosphorylatable Ser or Thr residue (Pearce et 
al. 2010). The inactive PKA exists as a tetrameric holoenzyme comprising a 
dimer of two regulatory subunits (PKAr, with four isoforms: rIα, rIβ, rIIα, and 
rIIβ) and two catalytic subunits (PKAc, with three main isoforms: α, β, γ). 
Whereas, the proteins PKAcα and PKAcβ are the most extensively studied 
isoforms of PKAc possessing the highest catalytic activity in human cells 
(Søberg et al. 2013). There are two other, less studied, kinases related to PKA: 
protein kinase X (PRKX) and Y-linked protein kinase (PRKY) (Pearce et al. 
2010). The function of both proteins has yet to be established.  
The substrate consensus sequence of the PKAc is Arg-Arg-X-Ser-X, where 
X is any amino acid residue (Poteet-Smith et al. 1997). PKAc (often α isoform) 
is a protein that is simple to produce and it is often used as a model for other 
PKs (Taylor et al. 2012).  
The classical activation mechanism of PKAc is prompted when extracellular 




second messenger bind to the PKAr dimer leading to the release of PKAc 
(Skålhegg and Taskén 1997). Active PKAc can diffuse to different cellular 
compartments and modify functions of various proteins. For example, 
phosphorylating cAMP response element-binding transcription factor (CREB) 
regulates gene transcription [Figure 1, (Shabb 2001)]. The specificity of PKA 
signalling is also affected by the subcellular localization of PKA. The com-
partmentalization of PKA is largely regulated by A-kinase anchoring proteins 
(AKAPs) (Wong and Scott 2004; Pidoux and Taskén 2010). 
 
Figure 1. Classical scheme of activation of PKAc and phosphorylation of CREB at 
Ser133. Phosphorylation activates CREB which induces the transcription of DNA and 
production of proteins. 
 
 
Due to the salient role of PKAc in normal physiology, it is expected that 
dysregulation of PKAc in disease has been also an interest of research 
(Esseltine and Scott 2013). For example, progressive and congestive heart 
failure, also onset of certain arrhythmias have been linked to dysregulated 
phosphorylation by PKA (Chen et al. 2008; McKinsey and Olson 2005). 
Besides cardio diseases, PKA has been also linked to other conditions, e.g. the 
Cushing´s disease, which is caused by excess of glucocorticoid production in 
adrenocortical tumours (Lacroix et al. 2015). Studies have revealed that in case 
of the Cushing´s disease the reason for higher basal activity of PKA is caused 
by the mutation of the gene encoding PKAcα (Di Dalmazi et al. 2014).  
Higher levels of PKA activity in blood serum of cancer patients (e.g.,  breast, 
colon, renal, rectal, prostate, lung, adrenal carcinoma, and lymphoma) has been 
reported (Cho et al. 2000; Cvijic et al. 2000; Kita et al. 2004; Wang et al. 2007; 
Moody et al. 2014). These instances reveal that PKA can be used as a drug 
target for various diseases, but also as a biomarker for cancer (Moody et al. 
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2014). A successful example is an anti-cancer drug AT13148 that inhibits PKA 




Similarly to PKA, CK2 is also composed of two catalytic subunits (α or α’) and 
two regulatory (β) subunits, and the formula of heterotetramer could be either 
α2β2, α’2β2, or α’αβ2. Unlike PKAc, CK2α (and CK2α’) is enzymatically active 
separately and also within the tetrameric complex. Furthermore, although the 
phosphorylation of enzymes often acts as an on/off switch, the activity of 
catalytic subunit of CK2 is not related to its phosphorylation status. Thereby, 
not activity, but the selection of substrate of CK2 is regulated by the means of 
its localization, phosphorylation, and protein-protein interactions. For example, 
the phosphorylation of the subunits of CK2 by Cdk1 in a cell cycle-dependent 
manner controls the functional specificity of CK2 due to different protein-
protein interactions (Litchfield et al. 1991). 
In 2009 it was estimated that circa 20% of protein phosphorylations are 
performed by CK2 (Salvi et al. 2009). However, a recent study postulates that 
this evaluation may be an over-estimation. The results of comparative SILAC 
(stable isotope labeling with amino acids in cell culture) phosphoproteomics 
analyses indicated that only 10% of the phosphosites were reduced by CK2α or 
CK2α' negative cells, consistent with their generation by CK2 (Franchin et al. 
2017a). Nevertheless, the role of CK2 in overall phosphoproteome could not be 
overemphasized. 
Analysing the possibility for such pleiotropy leads to the structure of the 
substrate binding pockets. The nucleotide-binding pocket makes CK2 eminent 
in many ways. First of all, CK2 is currently known to be the only PK capable of 
efficient transferring of the γ-phosphoryl group of ATP and GTP (Rodnight and 
Lavin 1964; Becher et al. 2013). Secondly, due to the presence of larger amino 
acid residues in the nucleotide binding site, the pocket is slightly more open yet 
smaller compared to most PKs (Niefind et al. 1999; Cozza et al. 2010). The 
protein/peptide binding pocket affects negatively charged proteins and peptides. 
Namely, CK2 is an acidophilic serine/threonine kinase that catalyses phospho-
rylation of proteins with a consensus sequence of S/T-X-X-D/E/pS/pY, where X 
is any amino acid residue, and it also exhibits tyrosine kinase activity in 
mammalian cells (Vilk et al. 2008). The consensus sequence is usually 
complemented with additional acidic residues (Marin et al. 1986; Salvi et al. 
2009). The small consensus sequence present in a large number of phospho-
rylatable proteins relates the kinase to almost every signalling pathway in a cell. 
For example, CK2-catalysed phosphorylation of Hsp90 and Cdc37 regulates 
protein folding (Figure 2.A), MAP2K2 and MEN1 dictate cell growth and 
proliferation, MDC1 and RAD51 have been related to DNA damage response, 
and cysteine-aspartic acid protease caspase 3 (CASP3) and PTEN to apoptosis 
[Figure 2.B (Rabalski et al. 2016)]. Notably, upon activation of caspases 
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approximately 14% of the kinome is cleaved (Duncan et al. 2011; Lüthi and 
Martin 2007). Although it was known earlier that CK2 regulates the activity of 
CASP3, it was just recently demonstrated that CK2α´ plays the most important 




Figure 2. Role of CK2 in signalling pathways. A) Phosphorylation of kinase-specific 
co-chaperone Cdc37 is critical for binding of PKs and for activity of chaperone. Active 
Cdc37 cooperates with Hsp90 (heat shock protein 90) to assist in the correct folding and 
functions of many signalling PKs. CK2 itself is also a client of Cdc37, and Cdc37 is 
required for optimal activity of CK2, thus these proteins together are forming a positive 
regulatory feedback loop. In conclusion, CK2 mediated regulation of the activity of 
Cdc37 has an important role in cell division, cell cycle control, but also tumour pro-
gression. The scheme is adapted from Ref. (Pinna 2013). B) The role of CK2 in the 
control of cell survival/apoptosis via caspase pathways. First, the phosphorylation of 
procaspase-3/9 (Pro-CASP3, Pro-CASP9) protects them from cleavage by caspase-8 
(CASP8); phosphorylation of procaspase-9 (Pro-CASP9) prevents the formation of 
CASP9. These events, in turn, prevent the activation of CASP3. Second, the phosphory-
lation of CASP3 directly inactivates it. Third, the phosphorylation of the targets of 
CASP3 [e.g., HS1 (actin-regulatory adaptor protein), CX 45.6 (gap junction-forming 
protein, connexin 45.6), pS2 (estrogen inducible protein), and PTEN (phosphatase and 
tensin homolog)] prevents the cleavage of these prosurvival proteins by CASP3 (Pinna 
2013; Turowec et al. 2013). C) CK2 plays an important role in agonist-induced platelet 
activation through the regulation of PI 3K (phosphatidylinositol-4,5-bisphosphate 3-
kinase) pathways. CK2-mediated inhibition of PTEN leads to activation of downstream 
targets of the PI 3K pathways including PDK1 (3-phosphoinositide-dependent protein 
kinase-1), Akt (protein kinase B), and GSK3β (glycogen synthase kinase 3 beta). The 
scheme is adapted from Ref. (Ryu and Kim 2013). 
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CK2 is a pleiotropic, constitutive active PK that plays important roles in many 
cellular processes [reviewed in (Guerra and Issinger 2008)]. Aberrant CK2 
activity has been associated with a number of diseases. Most often, the role of 
CK2 in progression of cancer has been acknowledged (Ortega et al. 2014). The 
latter is not unanticipated, first because CK2 regulates numerous processes that 
are essential for cancer development (Rabalski et al. 2016). Second, cancerous 
cells express high level of CK2 of which they are addicted to (Ruzzene and 
Pinna 2010). As a significant proportion of substrates of CK2 is involved in cell 
death and survival, CK2 is a potential target for treatment of cancer (Trembley 
et al. 2017; Ahmad et al. 2007). 
CK2 also plays a role in the non-cancer diseases. For example, CK2 is a 
regulator of thrombus formation, affecting multiple interactions of platelets, 
leukocytes and endothelial cells (Ampofo et al. 2015). Nakanishi et al. reported 
in 2008 that stimulation of platelets with PAR1-activating peptide and thrombin 
resulted in an increase in the activity of CK2. Ryu et al. confirmed the role of 
CK2 in platelet aggregation by regulating the expression level of phosphory-
lated PTEN, and, in turn, PI 3K-dependent signalling (Figure 2.C). Inhibition of 
CK2 leads to down-regulation of P-selectin and GPIIb/IIIa (Ampofo et al. 
2015). As CK2 regulates multiple interaction mechanisms that mediate the 
activity of platelets, inhibition of CK2 may also contribute to the future treat-
ment of diseases which accompany thrombosis. 
 
 
2.2. PROTEIN KINASE INHIBITORS 
PKs could be both, biomarkers for diagnosis of diseases in their early stages and 
targets for treatment of diseases. Evidently, there is an unmet need for methods 
and probes that enable comparative and quantitative analysis of blood samples 
for determination of abnormal levels of proteins. Equally important to afore-
mentioned is to balance PKs in disease. PKs are well druggable, i.e., they 
possess protein folds that favour interactions with drug-like chemicals. 45 years 
after the discovery of first PK in 1954, the first PK inhibitor Trastuzumab was 
approved by the FDA (Baselga et al. 1998). This monoclonal antibody targeting 
receptor kinase ERBB2 is used for the treatment of ERBB2-overexpressed 
breast cancer, but also for gastric and gastroesophageal cancer (Okines and 
Cunningham 2012; Roukos 2010). Around twenty large molecule PK inhibitors 
have been approved by the FDA since (Gharwan and Groninger 2015). Two 
years after the approval of Trastuzumab, FDA also approved the first small 
molecule PK inhibitor Imatinib for treating chronic myelogenous leukaemia by 
targeting mainly tyrosine kinase BCR-Abl (Roskoski). More than 35 small-
molecule PK inhibitors have received NDA approval as drugs in recent 16 years 
(Wu et al. 2015; Fabbro et al. 2015; Sharma et al. 2016; Rask-Andersen et al. 
2014b). 
According to PubMed database, the number of studies related to “PK drugs” 





largest category of drug candidates in clinical trials (Rask-Andersen et al. 
2014b), which explains the continuous interest into this field by academic 
research groups. These results of PK studies were compared to these of G 
protein–coupled receptor research (GPCRs), as both account for approximately 
20% of the established drug targeted portion of the genome (Rask-Andersen et 
al. 2014a). Despite similar druggability, the number of FDA approved drugs 
targeting GPCRs is approximately 15-fold larger, approaching 500 (Hauser et 
al. 2017), whereas nearly half of these were accepted before 1990 and less than 
7% within past 6 years (Santos et al. 2016). The distinctive difference in the 
number of accepted drugs could be somewhat linked with the escalation of 
interest in GPCRs as drug targets approximately ten years before PKs. However 
the level of GPCR-related academic research has remained on the same level for 
the last 15 years according to PubMed search (Figure 3), which also coincides 
with the decreased number of approved drugs per year. The comparison of 
druggability of GPCRs and PKs as target proteins with the number of approved 
drugs and also with the number of related studies indicates that there is potential 
and space for more PK inhibitors in pharmaceutical industry and in academic 
research (Berndt et al. 2017). 
Figure 3. Number of publications related to phrase “protein kinase drug” and “G 
protein-coupled receptor drug” found in PubMed search engine. 
 
 
The construction of inhibitors of PKs has been mainly focussed to nucleotide-
competitive inhibitors. These small molecules mostly fulfil requirements of the 
Lipinski´s “Rule-of-five” (Lipinski et al. 1997), possess satisfactory inhibitory 
potency, and hold cell plasma membrane penetration properties. However, the 
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disadvantage of nucleotide-competitive inhibitors is the similarity of binding 
sites of the target kinase and more than other 3000 purine-binding proteins, 
which may lead to poor selectivity of the drug (Knapp et al. 2006; Haystead 
2006). For example, the study by Karaman et al. demonstrated that Staurospo-
rine inhibited 87% of tested PKs with binding constant value below 3 µM 
(Karaman et al. 2008). Nevertheless, there were also successful examples of 
ATP-competitive inhibitors disclosed in the paper, e.g., Lapatinib whose main 
target is ERBB2, inhibited 1% of tested PKs (Kd < 3 µM). Lack of high 
selectivity against a specific target may be also beneficial for a kinase inhibitor 
that aims to become a useful drug. For instance, an inhibitor targeting simulta-
neously several PKs that regulate the survival of cancerous cells can be an 
effective tool to treat cancer. However, non-selective inhibitors could possibly 
give rise to undesirable side-effects and are not suitable for analysing the 
biological function of the given PK (Klaeger et al. 2017). 
Structure of substrate protein binding pocket of PKs is less conserved, 
therefore construction of substrate-competitive inhibitors would lead to 
selective inhibitors. Structurally these inhibitors are usually peptides, therefore 
they often possess bad cellular uptake, intracellular instability, and low affinity 
for the target protein. For higher affinity peptide-type inhibitors should have 
large contact area with the target PK, therefore such peptides have higher 
molecular weight than small organic compounds binding to the ATP pocket of 
the kinase. For example, PKA inhibitor peptide alpha (PKIα), a 75 amino acid 
long peptide, inhibits PKAc with Ki value of 0.20 nM (Dalton and Dewey 
2006). Several technologies (see paragraph 2.2.2) have been worked out for 
improving cellular uptake and stability of peptidic inhibitors (Bogoyevitch et al. 
2005).  
Bisubstrate analogue (biligand) inhibitors could overcome the selectivity and 
specificity issues related to two aforementioned inhibitor types (Cozza et al. 
2015; Lavogina et al. 2010a; Parang and Cole 2002). The moieties of these 
inhibitors mimic two natural substrates that are conjugated into a single mole-
cule via a suitable linker. Simultaneous association with two regions of the 
target kinase leads to synergistic effect on affinity, as the binding free energy 
could be equal to the sum of the free energies for each component and an 
additional energetic factor deriving from entropy or enthalpy decrease (Jencks 
1981; Parang and Cole 2002). Various successful biligand inhibitors have been 
constructed, e.g., conjugate of ATP-γS and a peptide substrate (Lys-Lys-Lys-
Leu-Pro-Ala-Thr-Gly-Asp) possesses Ki value of 370 nM towards the core 
tyrosine kinase domain of the insulin receptor, cIRK (Parang et al. 2001); 
conjugate of isoquinoline sulfonamide-based H9 and (L-Arg)6 peptide with  
IC50 of 3 nM towards PKAc (Ricouart et al. 1991); and currently the most  
potent inhibitor of PKAc, the conjugate of 4-(piperazin-1-yl)-7H-pyrrolo[2,3-






In recent years medicinal chemistry research group at the University of Tartu 
has focussed its research activities to the development of biligand inhibitors and 
probes (called ARC-inhibitors and ARC-probes, respectively) for PKs (Enkvist 
et al. 2006; Vahter et al. 2017). The design of inhibitors has been guided by 
extensive structure-affinity studies and X-ray analysis of inhibitor:PK co-
crystals (Lavogina et al. 2009; Kestav et al. 2015). As a result, the affinity of 
several ARC-inhibitors towards PKs lies in the nanomolar to picomolar range 
(Ivan et al. 2016). 
The biligand inhibitors of basophilic PKs are bifunctional compounds 
(Figure 4.A) that according to results of X-ray analysis of ARC:PK co-crystals 
associate simultaneously with binding sites of both substrates of the PK. On one 
hand, each fragment of the molecule is contributing to the total binding affinity 
of the compound. On the other hand, the oligo-arginine fragment acts as a cell-
penetrating peptide (CPP; see paragraph 2.2.2) dragging the compound inside 
the cellular milieu (Uri et al. 2002; Räägel et al. 2009; Vaasa et al. 2010). The 
negatively charged ARCs targeting acidophilic PKs like CK2, however, require 
the application of a facilitated transport mechanism to penetrate the plasma 
membrane (Figure 4.B). 
 
Figure 4. Structures of ARC-type inhibitors targeting A) basophilic kinase PKAc and 
B) acidophilic kinase CK2. 
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The cellular uptake of fluorescently labelled arginine-rich ARCs (ARC-Photo 
probes) has been demonstrated with microscopy imaging (Uri et al. 2002; Viht 
et al. 2003; Räägel et al. 2008; Lavogina et al. 2010b; Vaasa et al. 2009) and 
the efficacy/functionality of internalized ARC-inhibitors using several assays, 
e.g., dissociation of cytoskeleton (Räägel et al. 2008), effect on parasitemia 
(Lavogina et al. 2014), and intervention in Haspin pathways (Kestav et al. 
2015). The potential off-targets of basic ARCs are negatively charged proteins, 
or nucleic acids DNA and RNA, while for acidic ARCs compounds possessing 
high positive charge could restrict their implementation as specific inhibitors. 
Thus, the regulation and monitoring of the intracellular concentration and loca-
lisation of the compound is of crucial importance for development of inhibitors 
for cellular studies. 
 
 
2.2.2. Methods for Cellular and Targeted Delivery 
As mentioned earlier, PK inhibitors could be applied as drugs or as probes for 
studying involvement of PKs in signal transduction pathways or mapping the 
localization of PKs in cells. However, the cell plasma membrane often limits 
the uptake of inhibitors/probes. Several technologies have been described for 
supporting and directing the transport of these compounds into cell interior. For 
example, the application of CPPs has opened several new avenues for bio-
medical research and therapy (Frankel and Pabo 1988; Rothbard et al. 2000; 
Guidotti et al. 2017). Within 30 years since their discovery, several CPP-con-
jugated compounds have entered into clinical trials (Vasconcelos et al. 2013). 
CPPs usually comprise up to 30 amino acid residues, whereas arginine-rich 
peptides form the most thoroughly studied group of CPPs (Nakase et al. 2004; 
Brooks et al. 2005; Futaki 2006; Kosuge et al. 2008; Torchilin 2008). Positively 
charged guanidinium groups of arginines form charge-reinforced hydrogen 
bonds with carboxylates, phosphates, and/or sulphates on plasma membrane, 
enabling CPPs to enter the cells using different transport mechanisms (Mai et 
al. 2002; Dom et al. 2003; Herce et al. 2014; Mitchell et al. 2000). The mecha-
nism and efficiency of uptake of arginine-rich CPPs is mostly dependent on the 
total charge of the compound and concentration of the compound in incubation 
solution (Ma et al. 2012). At lower extracellular concentrations, the main 
peptide uptake mechanism is endocytosis; if surpassing the critical threshold 
concentration, arginine-rich peptides directly penetrate the plasma membrane. 
Clearly, direct penetration mechanism is preferred over the endosomatic path-
way, as it is faster and bypasses the possible endosomatic entrapment. The 
aforementioned critical threshold concentration for peptides comprising D-
enantiomers of amino acids is usually lower (1…5 μM) than that for peptides 
formed of L-enantiomers of amino acids (10 μM) (Ma et al. 2012; Vaasa et al. 
2010; Duchardt et al. 2007; Tünnemann et al. 2008). Here faster proteolytic 
degradation of L-peptides in incubation solution and in intracellular milieu may 
be one factor that affects these results. It has been also proposed, that the reason 
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for the lower threshold concentration of D-peptides is because the reduction of 
internalization via endocytosis might accelerate accumulation of peptide at the 
plasma membrane, which might trigger direct translocation more rapidly 
(Verdurmen et al. 2011). 
Second large family of delivery vehicles act through targeting overexpressed 
receptors on pathological cells. Examples of receptor-targeting molecules 
include monoclonal antibodies (Lambert 2013), receptor antagonists (Carpenter 
et al. 2009), and oligopeptides (Li and Cho 2012). The conjugation of the ligand 
to a therapeutic drug helps to facilitate the transport of the drug specifically into 
the pathological cell. Directed delivery (also called targeted delivery) thus 
enables to avoid unwanted effect to healthy cells. However, as the drug is 
transported via receptor-mediated endocytosis, efficiency of which is directly 
related to the number of receptors available for transport on plasma membrane, 
only a limited amount of drug is delivered into a cell (Paulos et al. 2004). 
Another disadvantage sometimes related to endocytic mechanism is the low 
cytosolic release rate (Ma et al. 2012). Therefore, the drug must be effective 
already at very low concentrations. 
One of the most thoroughly studied transport ligands is folate which acts 
through folate receptors (Saul et al. 2003; Sudimack and Lee 2000; Vlahov and 
Leamon 2012; Tyagi 2016). Folic acid is crucial for the proliferation and 
maintenance of all cells, mainly as it is needed for the synthesis of nucleic 
acids. Folic acid is transported into the cells via three transport routes: low 
affinity reduced folate carrier, proton-coupled folate transporter, and folate 
receptor (Matherly et al. 2007; Zhao et al. 2009; Kamen and Smith 2004). 
While the healthy cells ensure their folate supplies mainly with the first two 
mechanisms, cancerous cells obtain their normal folate levels via highly ex-
pressed folate receptors (Ross et al. 1993; Parker et al. 2005). The latter 
peculiarities are exploited in the selective transport of drugs. The folate-drug 
conjugates exhibit no affinity for the reduced folate carrier or proton-coupled 
folate transporter, yet they bind to folate receptors with high affinity [Kd (FRα) 
≈10-9 M (Parker et al. 2005)]. As for other receptor-mediated transport systems, 
the rate of receptor recycling between cell surface and inside cellular milieu, 
and the number and accessibility of folate receptors on the cell surfaces are 
important features in delivery of folate mediated drug. It has been found that it 
takes approximately 8…12 h for an folate receptor to unload their cargo and 
recycle, and that an average cancer cell expresses up to 107 folate receptors 
(Paulos et al. 2004). Administration of a saturating dose of a folate-drug con-
jugate more frequently than the recycling rate will result in high concentration 
of extracellular drug, which can increase the toxicity to surrounding tissue. One 
promising example of the conjugates in clinical trials is folic acid-Tubulysin 
conjugate EC1456, which is studied for a treatment of advanced solid tumours 
(Reddy et al. 2009). 
While CPPs and conjugation of folate enhances the cell plasma membrane 
penetration of compounds on a single cell level, peptides called “vascular zip 





Figure 5. The delivery of a cargo with the iRGD system is a two-step process. First, the 
cyclic peptide iRGD containing an internal RGD motif binds to a αvβ5 integrin on a 
tumour specific vasculature. The binding supports the proteolytic processing of the 
iRGD system which results in a linear peptide called CendR, revealing the C-terminus 
of RGDK/R sequence. Second, the RGDK/R motif binds to Neuropilin-1, inducing the 
export of CendR-cargo conjugate from blood vessels and import into tissue/cell. The 
figure is adapted from (Sugahara et al. 2009). 
 
2.3. METHODS FOR CHARACTERISING INHIBITORS 
The research on new inhibitors aims to establish how lower doses of the drug 
can be used and how toxic effect caused by the interaction of drug with non-
target PKs and other biomolecules can be reduced. Hence, the design of in-
hibitors is directed towards high-affinity and selective inhibitors, but also 
towards effective delivery systems and successful release of the inhibitors into 
cellular milieu. In order to measure important parameters (binding affinity, 
zip code method has been successfully used to facilitate delivery of drugs, 
imaging agents, viruses and/or nanoparticles to tumour vasculature, acute brain 
injuries, hippocampus of brain with Alzheimer’s disease, and also to uterine 
vasculature (Paasonen et al. 2016; Cureton et al. 2017; Simón-Gracia et al. 
2016; Mann et al. 2017; Teesalu et al. 2013). 
structure of these peptides is based on the distinct biochemical signatures 
expressed on the vasculature in different tissues (Ruoslahti 2002; Ruoslahti and 
Rajotte 2000). A well-known example of such transporting systems is the iRGD 
peptide (Figure 5). Upon recognition of the first part (RGD) of the peptide by 
endothelial receptor specific for cancer vasculature (αvβ5 integrin), iRGD is 
cleaved by proteases (Sugahara et al. 2009). As a result, the remaining peptide 
(called CendR) is recognised by another receptor (Neuropilin-1) which directs 
the CendR moiety together with the attached cargo insid the cell. The vascular 
 
22 
selectivity, intracellular concentration, efficiency of regulation of cell´s physio-




2.3.1. Kd-Values of High-Affinity Compounds 
Historically, kinetic inhibition assays have been the most popular choice for 
characterisation of the inhibitors of PKs. These assays monitor the effect of the 
inhibitor to the phosphorylation rate of the substrate peptide/protein by a target 
kinase. A “gold standard” is the radioactive [γ-32P]-ATP method, where the size 
of the radioisotope is the closest to that of the physiological ATP, compared to 
other labels, e.g. fluorescence dyes (Jia et al. 2008). However, the kinetic assays 
are often expensive, time-consuming, and require special assay components 
(suitable substrate for phosphorylation, sufficiently catalytically active kinase, 
and reagents for measuring the phosphorylation reaction).  
In recent years different binding/displacement assays have gradually re-
placed kinetic assays  (Davis et al. 2011; Fabian et al. 2005; Bamborough et al. 
2008). In the course of binding/displacement assays the displacement of a probe 
(tracer) from the complex with the PK by the compound under evaluation (e.g., 
inhibitor, displacer, ligand, binder, or replacer) is monitored. These assays give 
information about the binding affinity of the inhibitor to the target PK. The 
binding/displacement assays have many advantages, e.g., simplicity, quickness, 
amenability for automation, and wider range of resolvable dissociation cons-
tants, especially when applying high-affinity probes (Vaasa et al. 2009; Huang 
2003). 
Most of the PK inhibitor-based drugs on the market possess biochemical Kd 
values in nanomolar range (Karaman et al. 2008). However, in cells inhibition 
of many PKs occurs only at super-micromolar concentrations of these 
inhibitors. This is due to high concentration of the co-substrate ATP in cells 
(1...10 mM), substantially up to 1000-fold surpassing Km values for PKs 
(1...1000 μM) (Knight and Shokat 2005). The substantially restricted inhibitory 
potency of inhibitors competing with intracellular ATP leads to the need for 
highly potent inhibitors possessing picomolar Kd values. By the virtue of the 
broadened analysis possibilities (e.g., analysis of protein structure and protein-
inhibitor complexes), the construction of new inhibitors and higher affinities of 
the inhibitors towards targets have been achieved (Tal-Gan et al. 2010; Xu et al. 
2009; Zhang et al. 2009; Lavogina et al. 2009; Noble et al. 2004). 
Nevertheless, evaluation of compounds with very high affinity towards the 
target protein is still experimentally challenging (Murphy 2004). As an 
example, if determining the affinity of the inhibitor by displacing the probe 
from the complex with PK, one parameter that characterises the precision of 
interpretation of IC50 value from displacement curve is the slope of the curve 
(also called Hill´s slope). The Hill´s slope is mainly determined by the affinity 
of both, the inhibitor and the probe towards the protein, and the concentration of 
23 
the probe (Figure 6.A). If the Kd of the inhibitor is too low compared to the ratio 
of the concentration and the KD of the probe, the Hill´s slope deviates from -1 
(thus locating in the so called tight-binding region). In these conditions the 
correct interpretation of the IC50 value is complicated mainly due to high 



























Figure 6. A) Simulation of displacement curves at different concentrations of the probe 
[cPK = 0.5 nM, KD,probe = 0.02 nM] in the dilution series of high-affinity inhibitor 
(Kd.inhibitor = 0.003 nM). Hill´s slope deviates from -1 if the concentration of the probe is 
decreased to critical value. B) Increase of the concentration of the probe leads to 
increase of the IC50 value. 
 
 
One possibility to shift the displacement curves away from the tight-binding 
region is to utilize higher concentrations of the probe (Figure 6) or a higher-
affinity probe (Huang 2003). Nevertheless, the applicability of this approach is 
often restricted because of lack of a suitable probe or strong signal of the free 
probe that interferes with the signal of the protein-bound probe. Accordingly, in 
case of analysing high-affinity inhibitors in a displacement assay, the selection 
of the probe is of crucial importance and sets limits to the range of affinities of 
inhibitors that can be determined. 
Another important aspect of characterization of tight-binding inhibitors is the 
choice of the parameter that can be used for their comparison. In case of 
displacement assays, IC50 values are usually compared. However, as was 
demonstrated in Figure 6, IC50 values depend on assay conditions: increased 
concentration of the probe leads to increase in the IC50 value. According to the 
Cheng-Prusoff equation, increase of the ratio of concentration of the applied 
probe and its affinity towards target kinase leads to bigger difference of IC50 and 
Kd (or Ki) values of the inhibitor (Cheng and Prusoff 1973). Kd, on the contrary, 
is not dependent on the concentration of PK, affinity or concentration of the 
probe, and it is directly related to the binding energetics (binding free energy 
change, ΔGbinding) (Copeland 2013; Schwartz and Murray 2011). The IC50 value 
obtained from the displacement curves could be converted to Kd by Cheng-
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Prusoff equation or by more exact equation derived by Nikolovska-Coleska 




The application of ARC(Photo) photoluminescent probes enabled the deter-
mination of low picomolar Kd-values of inhibitors of PKs in binding/displace-
ment assays. The ARC(Photo) probes possess the structure of biligand ARC-
inhibitors described in chapter 2.2.1 and additionally comprise a fluorescent dye 
in the C-terminus of the peptidic moiety. The dissociation constant Kd of com-
pounds determined in binding/displacement assays well coincide with the 
values of inhibition constants Ki of the same compounds as determined in 
kinetic/inhibition assays for ATP-competitive, substrate protein-competitive, 
and biligand inhibitors (Enkvist et al. 2011; Vaasa et al. 2009). The latter result 
shows that ARC-probes bind only to active forms of the kinase.  
The biligand structure of the probes enables the determination of binding 
constants for ATP-, substrate protein-competitive, and biligand inhibitors (Viht 
et al. 2007; Enkvist et al. 2011). Also, the binding equilibrium of probe:PK 
complex in solution is achieved quickly, which allows the use of short incu-
bation times in displacement assays (Viht et al. 2007; Vaasa et al. 2009; Enkvist 
et al. 2011). 
There are mainly two types of ARC(Photo) probe differing from one another 
by the photoluminescent properties of the ATP-competitive moiety and the 
resultant possible applications of the different probes. ARC-Fluo probes are 
designed for assays with fluorescence anisotropy (FA) readout. Whereas, ARC-
Lum(Fluo) probes possess photoluminescent properties that make possible their 
application in assays with FA readout as well as in assays using time-gated 
measurement of luminescence intensity (TGLI) (Vaasa et al. 2009; Enkvist et 
al. 2011; Ligi et al. 2016).  
The range of resolvable binding affinities, as determined in assays with FA 
readout, is limited by the affinity of the probe (Huang 2003). ARC-Lum(Fluo) 
probes, on the other hand, possess unique photoluminescent properties which 
greatly expand their applicability in biochemical assays using TGLI (Enkvist et 
al. 2011; Ligi et al. 2016). First, upon pulse-excitation with near-UV radiation 
(between 300...370 nm) the probe reveals characteristic PK binding-responsive 
photoluminescence with slow (microsecond scale) decay. The latter pheno-
menon allows the bypass of short-lifetime (nanosecond-scale) background 
fluorescence of compounds present in the assay system (Enkvist et al. 2011). 
Second, very weak signal of free probes and high affinity of probes enable their 
employment for determination of dissociation constants of both tight-binding 
and low affinity inhibitors (Huang 2003; Vaasa et al. 2009; Enkvist et al. 2011). 
The Jablonski diagrams of bound and unbound ARC-Lum(Fluo) probe are 
presented in Figure 7. 
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Figure 7. The simplified Jablonski diagram of a PK-bound ARC-Lum(Fluo) probe 
describing formation of the long lifetime photoluminescence signal at the emission 
wavelengths of the acceptor fluorescent dye. For clarity, transitions between electronic 
states leading to short life-time photoluminescence (fluorescence) have been omitted. 
The donor-luminophore D is excited with a pulse of near-UV radiation. The excited 
donor-luminophore (1D*) can dissipate its energy via radiative (not shown) and 
nonradiative processes (curved lines), such as internal conversion (IC) and vibrational 
relaxation (VR). 1D* can also change its spin by intersystem crossing (ISC) and go into 
excited triplet state 3D*. Inside the catalytic pocket of a PK the concentration of the 
quencher, such as dissolved molecular oxygen, is greatly reduced thus the energy is 
stored in 3D*. In the presence of the acceptor fluorophore in close proximity to donor 
the energy is released gradually from T1* to the acceptor fluorophore via FRET. This 
leads to the relaxation of the donor to the ground singlet state 1D and formation of 1A* 
that thereafter emits a photon and relaxes to the ground singlet state (1A). To conclude, 
this type of energy transfer (inter-chromophore triplet-singlet energy transfer) occurs if 
the tandem probe is bound to a PK and the 3D* state of the phosphor is shielded from 
dissolved quenchers (e.g., molecular oxygen) and molecular motions are restrained. The 
emission spectrum of an ARC-Lum(Fluo) probe coincides with the fluorescence 
spectrum of the attached dye. The emission decay time of the tandem luminophore is 
defined by the stability of the excited triplet state of the donor phosphor. The rate and 
efficiency of the transfer also depend on the distance between the chromophores. 
 
 
ARC-Lum(Fluo) probe library contains compounds that could be applied for 
analysis of binding affinities for inhibitors of PKAc, ROCKII, PKG, Haspin, 
AKT3, Pim1, Pim2, CK2, and other PKs (Table 1). The resolvable range of 
inhibitor affinities if applying a specific probe is discussed in chapter 5.1.1.2. 
Besides determination of binding constants, the probes could also be used as 
sensitive tools for determining concentration of the active form of PKs in 
biochemical assays (Kasari et al. 2012) and mapping the activity of PKs in 







































































































































































































































































































































































































































































2.3.2. Intracellular Concentration:  
Importance and Determination 
Good cellular accumulation of the compound together with its appropriate 
intracellular compartmentalization are critical factors that pave the way for their 
successful application as PK inhibitor-based drugs and probes. Determination of 
the intracellular concentration of these compounds helps to establish amount of 
the ligand in cells that is necessary for regulation or monitoring of cellular 
activity of PKs. If used as probes to study the pathways with participation of the 
target PK, it would be necessary to minimise the intracellular concentration of 
the active compound in order to reduce the probability of its binding to other 
proteins and constituents of cells. Nevertheless, in order to cause effective inhi-
bitory effect, often high (micromolar) concentration of the compound in the cell 
is needed. As an example of successful inhibitor, imatinib (Gleevec) is exten-
sively transported into cells which could explain the remarkable effectiveness of 
the drug in causing apoptosis of leukemic cells (Widmer et al. 2006; Lipka et 
al. 2012). 
For several reasons both optimising the intracellular concentration of the 
inhibitor and knowing its affinity towards the PK are important. First, con-
centration of the compound lower than 10 µM would be advisable to reduce the 
probability of its binding to non-target proteins and non-specific binding that 
increases rapidly at concentrations above 10 µM (Knight and Shokat 2005). 
Second, the preferences for the concentration of the inhibitor are related to the 
amount (average concentration) of the target kinase in the cell, as that deter-
mines the stoichiometrical amount of the inhibitor needed (Knight and Shokat 
2005). Third, in a cell the drug has to compete with high (1…5 mM) con-
centration of ATP (Kennedy et al. 1999; Gribble et al. 2000). As the KM,ATP 
values for most PKs are in the low- to mid-micromolar range, for effective 
regulation of  activity of the PK, the concentration of ATP site-targeting inhi-
bitors in the cell should be about 10- to 100-fold higher than the Ki value of the 
inhibitor (Knight and Shokat 2005). Therefore, for the development of a suc-
cessful drug the intracellular molar amount of both the target PK and its 
inhibitor should be determined.  
Several experimental techniques enable the determination of intracellular 
concentration of compounds. Fluorescent label aids the quantification by high 
performance liquid chromatography (HPLC) with fluorescence detection (Lucas 
et al. 2016; Palm et al. 2006; Aussedat et al. 2006), SDS-PAGE (Mussbach et 
al. 2011), fluorescence-activated cell sorting (FACS) (Watkins et al. 2009; 
Nakase et al. 2004), fluorescence correlation spectroscopy (FCS) (Verdurmen et 
al. 2011), or the combination of the two (Rezgui et al. 2016). However, cellular 
uptake of a labelled compound (e.g., peptide) can be drastically different of that 
of the unlabelled counterpart. For unlabelled compounds, HPLC with mass 
spectrometer (MS) (Kralj et al. 2013a) and UV/Vis (das Neves et al. 2012) 
detectors, and matrix-assisted laser desorption/ionization time-of-flight MS 
(MALDI-TOF MS) (Burlina et al. 2005), have been applied. 
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Molar concentration of inhibitors has been disclosed in relatively rare cases 
as most of the publications only report the change in the intensity of fluore-
scence (or some other signal) separately or as normalized to some stable refe-
rence indicator (e.g., amount of total protein in the sample) (Lindgren et al. 
2004; Aussedat et al. 2006; Balayssac et al. 2006; Kralj et al. 2013a; Palm et al. 
2007). These data do not enable the estimation of the molar concentrations of 
molecules participating in signalling cascades in cells. 
There are two aspects complicating the expression of results as molar con-
centrations that should be considered. First, calculations for molar con-
centrations require knowledge about the volume of the cell, which is often an 
approximate value (similarly to the concentration of total protein in a cell). 
Second, differentiating between the internalised compound and the compound 
bound to the cell surface could be challenging. Oehlke et al. and Aussedat et al. 
solved the obstacle by chemical modification of the extracellular peptide 
(Aussedat et al. 2006; Oehlke et al. 1998), and Lindgren et al. applied 
enzymatic digestion (Lindgren et al. 2000). 
Depending on the specific study area and requirements of the method 
parameters (e.g., speed, price), a suitable technique can be chosen. As each of 
the analytical methods has its pros and cons, often different methods are used in 
parallel – thus a better understanding of the internalisation process could be 
obtained.  
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3. AIMS OF THE STUDY 
Based on the high demand for PK inhibitors as drugs and as diagnostic agents, 
the main aims of this study were the development/refinement of methods for 
characterisation of high-affinity PK inhibitors and the development of biligand 
ARC-inhibitors for regulation of cell physiology. Accordingly, the following 
tasks were set for the study. 
 Establishment of the applicability of ARC-Lum(Fluo) probes for characteri-
zation of high-affinity inhibitors of PKs. 
 Elaboration of a HPLC method for determination of intracellular con-
centration of labelled and unlabelled ARCs. 
 Development of a selective and potent biligand inhibitor for CK2. 
 Modification of the structure of biligand inhibitors and demonstration of 
their applicability for regulation of activity of cellular PKs (in particular 
CK2 or PKA). 
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4. MATERIALS AND METHODS 
4.1. DISPLACEMENT ASSAYS FOR DETERMINATION  
OF BINDING AFFINITIES 
The binding affinities of ligands were determined in displacement assays as 
described earlier (Vaasa et al. 2009; Roehrl et al. 2004; Kashem et al. 2007; 
Vahter). The assays with CK2 were carried out in 4-component buffer [50 mM 
HEPES (Sigma), 150 mM NaCl (Riedel-de Haën), 0.005% Tween® 20 
(Sigma), 5 mM DTT (Fluka), pH 7.5] and with PKA in 5-component buffer 
[additional 1.5 µM or 7.5 µM BSA (Sigma) for higher- and lower-affinity 
inhibitors, respectively]. Buffer solutions were made in MilliQ ultrapure water 
(Millipore Corporation). 
The concentrations of stock solutions of ligands and probes were determined 
spectrophotometrically (NanoDrop 2000c, Thermo Scientific) in a buffer or in 
DMSO (Sigma Aldrich) by the reference to molar extinction coefficients 
determined previously: unlabelled compounds containing ATB-fragment,  
ε322nm = 23 000 M-1cm-1; unlabelled compounds containing TBBz-fragment, 
ε272nm = 10 000 M−1cm−1; ARC-1504, ARC-1139, ARC-1182, ε647nm = 250 000 
M-1cm-1; ARC-1530 and ARC-1042, ε558nm = 80 000 M-1cm-1; ARC-904, ARC-
1411, ARC-1222, and ARC-1012, ε260nm = 15 000 M-1cm-1 (Vahter; Enkvist et 
al. 2012; Vaasa et al. 2009; Enkvist et al. 2011; Kestav et al. 2015). For 
compounds comprising both, ATB and folate moiety (ARC-778), the molar 
extinction coefficient of ε306nm = 32 000 M-1cm-1 was calculated by summarizing 
the corresponding epsilon values (Vahter; Dántola et al. 2010). 
Full length human recombinant protein His-CK2α-His (Manoharan 2016) 
and PKAc (Lavogina et al. 2009) were prepared as described previously. The 
concentration of the PKs was determined before each displacement measure-
ment series in the direct binding assay using FA or TGLI readout as described 
previously (Vaasa et al. 2009; Vahter). The concentration of CK2α was 
determined by titration of the fixed concentration (20 nM) of PromoFluor-647-
labeled fluorescent probe ARC-1504 or 5-TAMRA-labelled luminescent probe 
ARC-1530 (available from Kinasera OÜ, Estonia) with the solution of the 
enzyme (2-fold dilutions). The concentration of PKAc was determined by 
titration of the fixed concentration of 5-TAMRA-labelled fluorescent probe 
ARC-1042 (20 nM) or PromoFluor-647-labeled luminescent probe ARC-1139 
(100 nM) with the solution of the enzyme (2-fold or 3-fold dilutions, respec-
tively). 
All assays were performed in the final volume of 20 μL in black 384-well 
polystyrene microplates with nonbinding surface (Corning #4514 or #3676). 
Experiments were run in 3…6 parallels with a PHERAstar platereader (BMG 
Labtech) 
The displacement assay was performed by mixing the compounds under 
evaluation at a single concentration or using a 3-fold dilution series. Before 
measurements, the microplates were incubated with orbital mixing with 300 
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rpm at 30 °C for 25…60 min. The difference of the value of fluorescence 
anisotropy (FA) compared to the FA-value of the free probe was registered on a 
PHERAstar platereader. For FA measurements, optical modules suitable for 
fluorescent dyes PromoFluor-647 {FP608B [ex 590(50) nm, em 675(50) nm]} 
and 5-TAMRA {FP607B [ex 540(20) nm, em 590(20) nm]} were applied.  The 
change in luminescence intensity was measured in time gate (time window) 
(TGLI) after time delay, upon excitation with a pulse of near-UV radiation. For 
TGLI measurements with the probe ARC-1530 optical module TRF805B1 [ex 
337(300…360) nm, em 590(50) nm] and with ARC-1182 optical module 
HTRF802D1 [ex 337(50) nm, em 675(50) nm], delay time of 80 µs, and gate 
time of 400 µs were applied. Assays with the probe ARC-1139 were performed 
with optical module HTRF802D1 [ex 337(50) nm, em 675(50) nm] and delay 
time of 50 µs, and gate time of 150 µs. 
Single concentration displacement measurements were used for the 
estimation of IC50 values of inhibitors according to Equation (1): 
  = , (1) 
 
where ICx is concentration of the inhibitor that leads to x% of the retained TGLI 
signal.  
The IC50 values were converted into [I]50 values (the estimations of the 
concentration of the free inhibitor when 50% displacement has occurred) in case 
of single concentration and full curve displacement assays, according to 
Equation (2): 
 [ ] = − [ ] , (2) 
 
where [EI]50 is the concentration of the enzyme:inhibitor (PKAc:inhibitor) 
complex in case of 50% displacement. The gained values were converted to 
dissociation constants (Kd,inh) according to the Cheng-Prusoff equation modified 
by Nikolovska-Coleska et al. (Nikolovska-Coleska et al. 2004) [Eq. (3)]: 
 , = [ ][ ], [ ], , (3) 
 
where [P]50 is the concentration of the free probe at 50% displacement, [E]0 the 
concentration of the free enzyme at 0% displacement, and KD,probe is the dis-
sociation constant of the complex of the probe and enzyme [see Supplementary 
Material 3 in Paper III for solution of Equations (2) and (3)].  
Data analysis was performed using GraphPad Prism software (version 5.01, 
GraphPad) and Microsoft Excel 2016 software. 
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4.2. CELLULAR ASSAYS 
The following cell lines were used in this work: human cervical cancer HeLa 
cells, Madin-Darby canine kidney cells (MDCK), human prostate cancer cells 
(PC-3), Chinese hamster´s ovary cells (CHO; all from American Type Culture 
Collection, ATCC), human prostate cancer cells (PPC-1, a kind gift from Dr. 
Tambet Teesalu, Cancer Biology Laboratory, University of Tartu), MIA PaCa-2 
cells (ATCC). The cells were grown on 6-well (Thermo Scientific™ 130184) 
culture plates (if not mentioned otherwise) in the medium (RPMI, DMEM, or 
DMEM/Ham’s F12, PAA Laboratories) supplemented with 10% FBS, 100 
U/mL penicillin, 100 μg/mL streptomycin (PAA Laboratories). Cell cultures 




4.2.1. Cell Counting, Determination of Viability and  
Diameter of the Cells 
15 μL of the cell suspension in DPBS and 15 μL of 0.4% trypan blue solution 
were mixed thoroughly. 10 μL of the obtained cell-suspension was added into 
dual-chamber counting slide (Bio-Rad); measurements with cell counter (TC-
10™, Bio-Rad) were performed 4 to 6 times. The cell counter provided the 
number of cells in 1 mL of cell suspension, percentage of live cells, histograms 
of diameters of alive and dead cells. The volume of the cells was calculated 
based on the formula of the volume of a sphere. 
 
 
4.2.2. Cytotoxicity Assay 
In case of cytotoxicity assays described in chapter 5.2.2.1, HeLa cells were 
grown in a 24-well plate (Nunc) to ∼50% confluence. Thereafter, the cells were 
washed with 2 mL of DPBS and incubated with ARC-1842, CX-4945 (Synki-
nase), TBBz, or ARC-1859 (all at 0, 1, 5, 10, or 20 μM) in serum-free DMEM 
high glucose medium containing 1% DMSO and 0.1% Pluronic F-127 (300 μL 
total volume) for 24 h in triplicate. Cells incubated in culture medium without 
DMSO and Pluronic F-127 were used as control. Thereafter each well was 
washed twice with 1 mL of DPBS and the solutions were transferred into a 
screw-capped tube. The cells were incubated with 0.25% trypsin, 0.1% EDTA 
(PAA Laboratories, 100 μL) for 2 min, suspended in DPBS (PAA Laboratories, 
1 mL), and added to the screw-capped tube. After centrifugation at 100 g for  
5 min, the supernatant was removed and the cells were resuspended in the 
indicator-free RPMI medium (200 μL). Thereafter the viability was determined 
as described in chapter 4.2.1. 
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4.2.3. Microscopy Analyses 
For microscopy analyses 15 000 cells were seeded on a 12-well microscopy 
chamber (Ibidi), cultured for 2 days. Thereafter, the medium was removed and 
the cell layer was washed two times with 200 μL of DPBS. ARC-1042 was 
diluted in serum- and antibiotics-free medium (total volume 100 μL, final con-
centration 10 μM). The cells were incubated with ARC-compound for 1 h or for 
24 h. After incubation, the solution of ARC was washed off with 200 μL of 
DPBS. During the microscopy analyses, cells were kept in 100 μL of the 
indicator-, serum-, and antibiotics-free medium at room temperature. 
The cells were imaged with a custom made microscope (TILL Photonics), 
using light source – oligochrome [excitation filter 520(35) nm, emission filter 
605(70) nm], exposure time – 100 µs, 10% of the maximal power of the lamp, 
and 20x oil objective. Images were analysed with ImageJ software (version 
1.46r, Wayne Rasband, National Institutes of Health). The intensities of the 
images were auto-scaled. 
 
 
4.2.4. HPLC and Western Blot Analyses 
Cells were seeded on 6-well (Thermo Scientific™ 130184; HPLC + Western 
Blot assays) or 12-well (Nunc; only Western Blot assays) culture plates. After 1 
or 2 days, ARC-compound of interest was diluted in serum- and antibiotics-free 
medium [DMEM High glucose or folate free RPMI (PAA Laboratories)], and 
added to the cells. The cells analysed with CREB phosphorylation assay were 
additionally treated with forskolin (Tocris) for 30 min after the treatment with 
inhibitors. All assays were performed at least in three replicates. After 
incubation, the cells were detached from the surface by solution of 0.25% 
trypsin, 0.1% EDTA (PAA Laboratories). After multiple washing steps with 
DPBS (PAA Laboratories), 15 µL of cell suspension was used for cell counting 
(see paragraph 4.2.1). The remaining cell suspension was lysed in cell lysis 
buffer (NP 40, Invitrogen) containing 1% of Triton-X (Sigma), protease inhi-
bitor cocktail (Sigma-Aldrich), 1 mM DTT, and 0.5 mM phenylmethylsulfonyl 
fluoride (AppliChem). The cell lysate was analysed by Western blot and/or 
HPLC.  
 
4.2.4.1. HPLC Analyses  
For HPLC experiments, the internal standard was added to the lysate and the 
proteins were precipitated with acetonitrile (lysate:acetonitrile ratio was 1:2 to 
1:3). Thereafter, the sample was centrifuged at 20 000 g and 4 °C for 30 min 
and thereafter the supernatant was dried in the rotational-vacuum-concentrator 
(RVC 2-25, Christ). Dry sample was re-suspended in 100 μL of buffer (50 mM 
HEPES, 150 mM NaCl, 0.005% Tween® 20, pH 7.5) or 50% ACN in water and 
analysed with HPLC. HPLC was equipped with a Kinetex XB-C18 or Luna C18 
(Phenomenex) analytical column (5 μm, 250 × 4.6 mm) maintained at 30 °C, 
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photodiode array detector SPD-M20A, fluorescence detector RF-20A xs, and 
autosampler SIL-20A. Acetonitrile/water (0.1% TFA) gradient at a flow rate of 
1 mL/min was used. 
Calibration solutions included the analyte and the internal standard in either 
buffer [50 mM HEPES, 150 mM NaCl, 0.005% Tween® 20, pH 7.5) or 50% 
ACN in water. The ratio of the peak area of analyte to that of the internal 
standard was used as the assay parameter. Peak area ratios were plotted against 
the corresponding concentration ratios, and standard calibration curves were 
obtained from least-squares linear regression analysis of the data. The linearity 
of the method was confirmed via evaluation of the calibration y-intercept and 
correlation coefficients. The intracellular concentration was calculated by the 
measurement model (4): 
 
_ = ∙ ∙ ∙        (4) 
 
where Cx-cell – intracellular concentration of ARC, Ax – peak area of the analyte, 
As – peak area of the internal standard, b – intercept, a – slope, Cs – 
concentration of the internal standard, Vfinal - final volume of the sample, Nca – 
number of living cells, dca – diameter of a live cell, Ncd - number of dead cells, 
dcd – diameter of a dead cell. 
The intracellular concentration of ARC was determined with applying the 
calibration curve. The calculations were performed with the software Microsoft 
Excel (2016). All uncertainties given in this thesis are expressed as combined 
uncertainty (Kragten 1994).  
 
4.2.4.2. Western Blot Analyses 
Proteins of cell lysates were separated by gel-electrophoresis and transferred to 
Western blot membranes. Proteins were identified by developing of the 
membranes with the following primary antibodies (analyses described in 
chapters 5.2.1 and 5.2.2.2.2): rabbit monoclonal antiphospho-Cdc37 (Ser13, 
Cell Signaling Technology Cat# 13248), rabbit monoclonal anti-Cdc37 (Cell 
Signaling Technology, Cat# 4793), rabbit polyclonal phospho-CREB-1 
(Ser133, Santa Cruz Biotechnology, Cat# sc-101663), and mouse monoclonal 
anti-α-tubulin (Abcam, Cat#  DM1A); and secondary antibodies: goat anti-
rabbit IgG alkaline phosphatase conjugate (Thermo Fisher Scientific, Cat# 
T2191), goat anti-rabbit alkaline phosphatase conjugate (AnaSpec, Fremont, 
CA, Cat# 28178), and goat anti-mouse (Applied Biosystems, Cat# T2129). 
Analysis of Western blot images was performed with ImageJ software (version 
1.46r, Wayne Rasband, National Institutes of Health) and the calculations of 
band intensities with Microsoft Excel (2016). More detailed procedure is 
described in Papers I and IV. 
35 
Western blot membranes (analyses described in chapter 5.2.2.1) were 
processed with the following antibodies: rabbit polyclonal antiphospho-NFκB 
p65 (Ser529, Abcam), rabbit monoclonal anti-NFκB p65, (Cell Signaling 
Technology), mouse monoclonal anti-Cdc37 (Santa Cruz Biotechnology), 
mouse monoclonal anti-β-actin (Sigma), and affinity-purified antiphospho-
Cdc37 (Ser13) antibody (a kind gift from Dr. I. Miyata, University of Kyoto, 
Japan). More detailed procedure is described in Paper II. 
 
 
4.2.5. Caspase-3 Activity Assays 
For determining the change in CASP3 activity, a Förster resonant energy 
transfer (FRET) biosensor (Casper3-GR, Evrogen company) was used com-
bined with the baculovirus-based BacMam transduction system (Rahnel et al. 
2017). The activation of CASP3 in cells leads to cleavage of the Asp-Glu-Val-
Asp sequence between the donor and acceptor fluorophores in the fusion protein 
and thus to elimination of FRET between the fluorophores. The reaction 
resulted in decrease of the emission of TagRFP and increase in the emission of 
TagGFP. Plasmid construction and generation of BacMam viruses was done as 
described earlier (Mazina et al. 2012). The cells were incubated with the virus 
for 3…4 hours, detached with 0.25% trypsin/0.1% EDTA, and seeded on a 
black clear-bottom 96-well cell culture plates (Ibidi, 89626) at the density of 50 
000…100 000 cells/well in 90 µL of culture medium, supplemented with 
sodium butyrate (Aldrich) at 10 mM final concentration for enhanced protein 
expression. The cells were further incubated for 24 h to allow the expression of 
Casper3-GR fusion protein. Before incubation with inhibitors, the cells were 
washed with DPBS. 
All reactions were carried out in the final volume of 100 µL. 10 µL of the 
10× concentrated ligand solution was added to the wells containing 90 µL of 
serum- and antibiotics-free medium and the image acquisition program was 
initiated. Autofocus was performed in the donor channel (Tag-GFP) and the 
acceptor channel (Tag-RFP) used the same focus. At least 4 images per well 
were captured in both channels, using the fluorescence plate reader mode on 
Biotek microscope Cytation5 at 37 °C, 5% CO2. The responses were measured 
every 30 min for the first 8 h, and every 60 min for the next 16 h. 
For excitation 465 nm LED cube was used for both channels, for donor 
(Tag-GFP) emission 525 nm cube and for acceptor (Tag-RFP) emission 593 nm 
cube were used. The change in acceptor/donor emission ratios was calculated 
using the equation 5: 
 ℎ    =  (5) 
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where I593_0, I525_0, I593_t, and I525_t refer to the mean pixel intensities of fluore-
scence emission for Tag-RFP and Tag-GFP proteins before and after the ligand 
treatment, respectively. The calculated values were plotted against time or 
concentration on the x-axis. Analysis of CASP3 activity images were performed 
with Gen5 software and the obtained data were analysed using Aparecium 
software (The GPCR Workgroup (Universtity of Tartu)) running in Matlab 
environment, and GraphPad Prism (5.04) program. For calculating of EC50 
values, the average values of Change in FI ratio of 11...16 h data points were 
used. The highest value of Change in FI ratio was unified for all data sets 
according to the control compound Staurosporine. 
 
 
4.2.6. Platelet Aggregation Assays 
Platelet samples [4 BC platelet concentrate, platelet content (180…340)×109, 
filtered] originating from healthy volunteer anonymous donors, were obtained 
from Tartu University Hospital. A general consent of every donor for use of 
his/her blood in scientific studies was preliminarily obtained. The study was 
approved by the Research Ethics Committee of the University of Tartu in 
accordance with The Code of Ethics of the World Medical Association 
(Declaration of Helsinki; 251/M-1, PI Dr. Asko Uri and Dr. Darja Lavogina). 
The measurement of platelet aggregation was performed by monitoring 
change in light transmission at 590 nm using PheraStar microplate reader. The 
assay was performed on transparent 96-well plates with flat bottom (Greiner, 
#655101). The pre-incubation of platelets and incubations during the assay were 
performed at 30 oC. Tyrode's buffer [120 mM NaCl, 5 mM KCl (AppliChem), 3 
mM MgCl2 (AppliChem), 2 mM CaCl2 (AppliChem), 45 mM glucose (Sigma), 
25 mM HEPES pH 7.4] was used as the main assay buffer. The final total 
volume in the assay was 120 µL. During the measurement, the following 
stirring conditions were applied: 1 mm double orbital shaking, shaking time 9 s 
before each cycle. Each measurement was performed as a triplicate; two 
independent experiments were performed on two separate days. 
Initially, the concentration of ADP (Sigma) suitable for induction of platelet 
aggregation was identified as follows. 2-fold dilutions of ADP were prepared in 
the assay buffer and pipetted together with blank solution (Tyrode’s buffer) 
onto the microplate. The measurement was started in the kinetic mode. After 3 
cycles (cycle time 27 s), the measurement was paused and platelets or buffer 
were added to the indicated wells; aggregation of platelets was monitored for 30 
min. Based on the results of this assay, we used final total concentration of 10 
µM or 25 µM ADP in the following measurements (25 µM was the lowest 
concentration that consistently induced significant aggregation and sufficient 
measurement window with low signal to noise ratio, 10 µM concentration was 
chosen as it has been used most often in platelet aggregation assays). 
In order to monitor the effect of CK2 inhibitors on aggregation, the 
following assay was performed. The solutions of CK2 inhibitors and the 
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reference compound Forskolin (Tocris, adenylyl cyclase activator) were pre-
pared in the assay buffer and then pipetted together with blank solution 
(Tyrode's buffer) onto the microplate. The measurement was started in the 
kinetic mode. After 3 cycles [cycle time 37 s (first experiment) or 73 s (second 
experiment)], the measurement was paused and platelets or buffer were added to 
the indicated wells; the microplate was then incubated for the indicated amount 
of time (30 min or 60 min) and the absorbance at 590  nm was constantly 
monitored. Finally, solution of ADP or buffer was added to the indicated wells 
and the measurement was continued for another 30 min. 
The final total concentration of inhibitors as well as Forskolin was 10 µM. 
The platelet count in each well was calculated as >1.8×107 according to the 
initial number of provided platelets and the dilution used. The data were 
analysed with GraphPad Prism 5.04. For the column diagrams, the absorbance 
values at ~15 min following addition of ADP were used. Unpaired t-test (two-
tailed p-value, confidence level of 95%) was used for the analysis of statistical 
significance of effects.  
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5. RESULTS AND DISCUSSION 
5.1. METHODS FOR CHARACTERIZATION OF PK INHIBITORS 
Drug development pipelines are focused on construction of PK inhibitors with 
the highest possible affinity. This approach leads to the application of lower 
doses of the drug and thus reduced possibility for toxic effects caused by 
interactions with non-target PKs and other biomolecules. Nevertheless, accurate 
evaluation of Kd values of high-affinity inhibitors is challenging. In this chapter 
we first introduce a high-throughput binding assay for determining affinities of 
PK inhibitors possessing Kd values in the sub-picomolar to sub-millimolar 
range. Second, an HPLC method was developed for determination of molar 
concentration of inhibitors in cells. 
 
 
5.1.1. Binding Assay for Determination of Affinities of  
PK Inhibitors (PAPER III) 
In the binding/displacement assay described in the paper III, ARC-Lum(Fluo) 
probes were used for determination of Kd values of PK inhibitors and probes. 
Unlike several other inhibitor-screening technologies (Lebakken et al. 2009), a 
single probe is used instead of a combination of antibody and fluorescent tracer, 
making the assay simpler, cheaper, and more accurate. Upon excitation with a 
flash of UV radiation, the probe in complex with the PK emits long-lifetime 
luminescence whose intensity is measured after delay in predetermined time 
window (TGLI measurement mode). Moreover, in case of such measurement 
conditions the signal from the free probe is negligible. As bound and free ARC-
Lum(Fluo) probes possess significant difference in photoluminescence pro-
perties, they are well usable in displacement assays for determination of the 
dissociation constants of competitive inhibitors (Figure 8). The physical back-
ground of photoluminescent properties of ARC-Lum(Fluo) probes has been 






Figure 8. ARC-Lum(Fluo) probe displacement assay based on TGLI. In case of low 
concentration of the inhibitor, the probe is bound into the binding pocket of the PK, 
resulting in intramolecular triplet to singlet FRET of ARC-Lum(Fluo) probe and 
emission of TGLI signal. In case of high concentration of the inhibitor under evaluation, 
the inhibitor:PK complex is formed. The displaced free probe upon excitation at 337 nm 
possesses no TGLI signal at the emission wavelengths of the dye.  
 
 
5.1.1.1. Determination of Optimal Concentrations of  
the Probe and PK 
The cost of high-throughput screening (HTS) measurements is largely com-
prised of the price of reagents used in the assay system. Suitable measurement 
conditions should satisfy the economic aspects of the assay [low concentration 
of assay components (PK, probe, and inhibitor)], but also result in accurate and 
precise outcome.  
We chose the enzyme PKAc, the probe ARC-1182, and three inhibitors 
[ARC-904, Kd (SD) = 0.22 (0.04) nM; ARC-1012, Kd (SD) = 2.5 (0.8) nM; 
ARC-1411, Kd (SD) = 0.003 (0.001) nM] for demonstration of the applicability 
range of the binding assay (Lavogina et al. 2009; Vaasa et al. 2009; Viht et al. 
2007; Ivan et al. 2016; Enkvist et al. 2006). 
The affinities of inhibitors under investigation dictate the suitable measure-
ment conditions, thus the inhibitors under study were divided into two groups: 
inhibitors possessing higher-affinity than the probe (Kd,inh < KD,probe) belonged to 
the first group and inhibitors with lower-affinity (Kd,inh > KD,probe) formed the 
second group. Our first aim was to establish the optimal concentration of the 
enzyme (PKAc) and probe (ARC-1182, Kd = 0.02 nM with PKAc) for analysis 
of Kd. Concentrations of aforementioned assay components was varied and the 
choice of optimal measurement conditions was made according to the values of 
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the following quality parameters: Z´-factor, SD of data points, and number of 
outliers. 
Taking into account the results of statistical tests and economic conside-
rations, for characterization of a lower-affinity inhibitor (Kd > 0.02 nM) the 
optimal measurement conditions were established: cprobe = 0.5 nM, cPKAc =  
0.5 nM. Reliable evaluation of higher-affinity inhibitors should be performed 
also at cPKAc = 0.5 nM. The choice of the concentration of the probe is dictated 
by the affinity of the inhibitor, as one key aspect for achieving accuracy is to 
ensure sufficient shift of IC50 value of the tested high-affinity inhibitor away 
from the tight-binding region. Thus, for evaluation of ARC-1411 it should be  
10 nM, but for evaluation of inhibitors possessing even higher affinity (Kd < 
0.003 nM) it should gradually higher (cprobe ≤80 nM). 
 
 
5.1.1.2. Simulation of Resolvable Range of  
Inhibitor Affinities 
Herein we propose a method for establishment of the resolvable affinity range 
of inhibitors using different assay setups. In practice, the Kd value is not directly 
determined from the measured data, instead it is converted from the IC50 value 
(total concentration of the inhibitor at the 50% displacement). The limit of re-
solvable Kd (LoKd) values of the assay system could be determined at the point 
where the relationship between these two parameters (IC50 and Kd) starts to 
deviate significantly from linearity. According to the classical Cheng-Prusoff 
equation (Cheng and Prusoff 1973), if the determined IC50 value is below 
10[E]T, the correlation deviates from linearity and IC50 values converge to the 
half-value of total concentration of PK (1/2 [E]T) in the assay system (Graph 1, 
blue dashed line). The latter value (IC50 = 1/2[E]T) determines LoKd in case of 
ideal, error-free measurement. In practice, the application of the classical 
Cheng-Prusoff equation below IC50 = 10[E]T leads to significant rise in mea-






Graph 1. Defining the value of LoKd. A) The relationship between logKd and log[I]50 – 
blue smooth line, and between logKd and logIC50 – blue dashed line, assay conditions: 
cPK = 0.5 nM, cprobe = 10 nM, KD,probe = 0.02 nM. Limit of Cheng-Prusoff (green dotted 
line) indicates the lowest value of IC50 which obeys the Cheng-Prusoff equation 
{log[I]50=log(10[E]T)}. Limit of Kd determination (blue dotted line) indicates the limit 
from where the determination of Kd values is not reasonable due to the sensitivity of the 
determined values to measurement errors {log[I]50 =log(1/2[E]T)}. The red dashed line 




Another possibility is to convert IC50 to free concentration of the inhibitor at 
50% of displacement ([I]50) as follows: [I]50 = IC50 - [EI]50, where [EI]50 is the 
concentration of enzyme:inhibitor complex at 50% of the displacement. This 
conversion enables the linearization of the relationship between Kd,inh and [I]50 
according to the logarithmic presentation of modified Cheng-Prusoff equation 
(6) (see Supplementary Material 3 of Paper III or paper by Nikolovska-Coleska 
et al., 2004 for details): 
 [ ] = , + 1 + [ ], + [ ], . (6) 
 
Compared to the classical Cheng-Prusoff equation, the modified Cheng-Prusoff 
equation is less affected by the measurement uncertainty up to [I]50 = 1/2[E]T 
(Graph 1, red dashed line and blue smooth line). Accordingly, we propose the 
application of the modified (and more precise) Cheng-Prusoff formula and the 
determination of LoKd at log[I]50 = log(1/2[E]T) (Graph 1, blue dotted line). 
Next, we plotted the results of the linearized and modified Cheng-Prusoff 
Equation (6) and determined LoKd values at different assay conditions. The 
concentration of the probe applied in the displacement assay mainly pre-
K
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determined the value of LoKd. The difference in LoKd values was 200-fold, 
from 12 pM (at 0.5 nM PKAc and 0.5 nM probe) to 60 fM (at 0.5 nM PKAc 
and 80 nM probe), simultaneously preserving good quality of the assay (Z’ > 
0.5). The upper threshold of the resolvable range of affinities, on the other hand, 
is limited by the artefacts (change in viscosity, optical interference, non-specific 
binding, solubility issues, etc.) related to required high concentration of 
inhibitor under investigation.  
The wide dynamic range makes ARC-1182 an excellent photoluminescent 
probe for determination of affinity of PKAc inhibitors possessing widely 
variable binding properties. As a comparison, the LoKd for commercially 
available LanthaScreen™ Eu Kinase Binding Assay applying time-resolved 
FRET measurements was calculated to be 20 pM (0.2 nM PKA, 100 nM probe) 
(Lebakken et al. 2009; Invitrogen). The main reason for much higher LoKd 
value, compared to our method, was low affinity of the probe “Kinase Tracer 
236” (KD,PKA = ~30 nM). 
The public toolbox (http://www.ut.ee/medchem/toolbox-fluorescence-probes) 
can be used for creating the map of resolvable affinities (including LoKd) for a 
variety of competitive probes at defined assay conditions. 
 
 
5.1.1.3. Single Concentration and Full Displacement Curve Analysis 
The single-concentration measurement is a rational, quick, and inexpensive 
method for screening compounds. Instead of construction of a full displacement 
curve, these measurements yield only one value corresponding to the displace-
ment percentage of the probe from its complex with the PK at fixed 
concentration of the inhibitor. The obtained values could be converted to IC50 
values according to equation (1). For reliability and accuracy reasons, the ICx of 
the single-concentration measurement should remain between 0.1 × IC50 to 10 × 
IC50 corresponding to 9% to 91% displacement of the probe from the complex 
with the PK (Copeland 2013). 
In order to compare the single concentration and full displacement curve 
assay, a random selection of inhibitors was analysed with both methods in 
similar conditions. Good correlation between the IC50 values obtained with 
these methods was demonstrated by R2 = 0.97 (Graph 2). The latter result 
confirms the rationality behind the use of single concentration measurements at 











Nevertheless, more precise Kd values of the selected inhibitors should be deter-
mined from full displacement curves. The previously discussed “map” facili-
tates a quick selection of the probe that possesses suitable concentration to 
affinity ratio and the concentration of the compound under evaluation (Fig. 10 
in Paper III). The details of the full analysis can reveal additional information 
about the compound-PK interaction and errors made during the experimen-
tation. For example, deviation from the steepness of the displacement from the 
expected value of -1 could point to possible pipetting errors, multiple binding 
sites of PK, nonspecific or tight-binding inhibition, aggregation or insolubility 
of the inhibitor (Copeland 2013). 
To summarise, we introduced a method applying a non-metal photolumine-
scent protein binding-responsive probe [ARC-Lum(Fluo) probe] for deter-
mination of dissociation constants of competitive inhibitors of protein kinases. 
High affinity (Kd = 20 pM) and low background signal of the free probe 
supports the determination of dissociation constants of tight-binding as well as 
low affinity inhibitors. The lowest Kd value of 60 fM can be accurately 
determined with the method. We also introduced the graphical presentation of 
the linearized Cheng-Prusoff equation in Paper III and showed multiple possi-
bilities for its application. Highlighting the quality and economic aspects of 
performing the measurements, the graphical presentation supports the decision 
making by reference to the assay conditions, calculation of LoKd values, and 
convenient conversion of IC50 values to Kd values. 
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5.1.2. HPLC-UV/Vis Based Method for Quantifying the 
Intracellular Concentration of Biligand Probes and Inhibitors 
There are several important properties of inhibitors that should be established 
for their successful implementation for cellular studies and drug development. 
Cellular uptake efficiency has gained less attention compared to inhibitory 
potency, selectivity, and cellular compartmentalization. Despite the importance, 
only a few papers quantify the uptake efficiency of inhibitors (Lucas et al. 
2016; Kralj et al. 2013b). 
In some cases, introduction of inhibitors to cells at lower concentrations is 
needed – for example, if applying inhibitors as optical probes (indicators) for 
mapping of concentration of PKs in cells. In this case, the intracellular con-
centration of the probe should be lower than concentration of PKs in cells. For 
application as drugs, often higher concentration is needed. In both cases, the 
probe/inhibitor has to compete with high (millimolar) concentration of  cellular 
ATP, at the same time avoiding nonspecific interactions (Knight and Shokat 
2005).  
We developed a HPLC method for measuring the molar concentration of 
biligand inhibitors and probes of PKs in cells. The studied probe ARC-1042 
comprised of ATP-site targeted fragment, a linker, a hexa-arginine moiety, and 


































































Figure 9. Structure of the biligand probe ARC-1042. 
 
5.1.2.1. Intracellular Compartmentalization 
We performed microscopy analysis of intracellular distribution of ARC-1042 
for two reasons. First, we wanted to clarify the localization of the compound in 
cells. Second, it was necessary to establish that the internalised compound is not 
substantially bound to cell plasma membrane, as this could add complexity to 
reliable determination of its intracellular concentration. 
Microscopy analyses revealed that ARC-1042 mostly localized in the cell 
nucleoli and cytoplasm, and less efficiently in the nucleoplasm of the tested 
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HeLa, MDCK, and PC-3 cells after 1 h incubation [Figure 10.A and Figure 7 in 
Ref. (Sinijarv 2013)]. Upon 24 h incubation period, ARC-1042 was perceptibly 
concentrated in nucleoli (Figure 10.B). In both cases, the images revealed low 
concentration of ARC-1042 in the plasma membrane – supporting the quanti-
tative HPLC analysis of the compound in cells. Similar results have been 
obtained by the studies about uptake efficiency of arginine-rich-CPPs and other 
ARCs (Vaasa et al. 2010; Kasari et al. 2012; Ma et al. 2012; Tünnemann et al. 
2008; Melikov et al. 2015). Previous studies suggest that the uptake mechanism 
of CPPs at 10 μM concentration is mainly direct penetration through the plasma 
membrane (Ma et al. 2012). The studies with a PK binding-responsive ARC-
probe [ARC-Lum(Fluo) probe, see chapter 2.3.1.1] revealed that the signal from 
nucleoli and partially from cytoplasm could be related to ARC:PK complex. 
The cytoplasmic ARC was partially either freely in the cytoplasm or bound to 
other cellular proteins (Vaasa et al. 2012). As the reference compound ARC-
1042 is structurally analogous to the particular ARC-Lum(Fluo) probe, similar 





Figure 10. Fluorescence microscopy images of localisation of ARC-1042 in HeLa cells 
and corresponding colour intensity plots. A) Incubation with 10 μM ARC-1042 for 1 h. 





Strong fluorescence intensity apparent in all cells pointed to efficient cellular 
uptake of ARC-1042 by all cells, whereby the average integrated fluorescence 
intensity (FI) was rather similar in different cells [FI(1 h) = (1400 ± 200) AU; 
FI(24 h) = (3100 ± 300) AU; n(cells) = 31, Figure 11]. The increase in the FI of 
cells incubated for 24 h compared to that of cells incubated only for 1 h points 
to substantial (two-fold) increase of intracellular concentration of the com-
pound. The colour plot (Figure 10.B) demonstrates at least two-fold higher con-
centration in the nucleoli compared to that of cytoplasm after a 24-hour 
incubation period in certain cells. Yet, this kind of contrast between distinct 
cellular compartments is not valid in case of all cells. 
 
 
Figure 11. Average integrated intensity of fluorescence signal of a single cell incubated 
for 1 h (blue) or 24 h (orange) with 10 μM ARC-1042. 
 
 
5.1.2.2. Determination of Intracellular Concentration 
The developed HPLC-UV methodology took into account the number, size, and 
viability of the cells to present the intracellular molar concentration of the 
compounds (Figure 12, Equation 4). The control over loss of analyte during 
sample preparation was achieved by applying an internal standard [detailed 
information in Ref. (Sinijarv 2013)]. The limit of quantification (LoQ) of ARC-










Figure 12. Methodology for determination of intracellular concentration of ARCs. 
 
 
The method was implemented to check how the intracellular concentration 
depends on the incubation time and concentration of the compound in the 
incubation solution. MDCK, HeLa, and PC-3 cells were incubated with 10 μM 
ARC-1042 for 1 h to 96 h (Figure 13.A). The uptake trends were similar in case 
of MDCK and HeLa cells, PC-3 cells revealed slightly different concentrations 
of the compound in the cells. The highest intracellular concentration of ARC 
[(352 ± 41) μM] was found in MDCK cells (72 h incubation). 
 
Figure 13. A) Intracellular concentration of ARC-1042 after various incubation times. 
Concentration of ARC-1042 in incubation solution was 10 μM. B) Uptake of ARC-
1042 at different concentrations of incubation solution, incubation time 24 h. Analyses 
were performed on three different days with three replicates each day. Data are 
expressed as average values of these measurements with combined uncertainty. 
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Results of HPLC and fluorescence microscopy analyses were in good con-
currence. The ratio of integrated FI values of 24 h and 1 h incubation in HeLa 
cells from microscopy experiments was 2.2, while the ratio of corresponding 
intracellular concentrations was 2.4. Approximate information about the con-
centration distribution within different cellular compartments could be also 
given by comparing the FI values with the average intracellular concentration of 
the compound. The average intracellular concentration after 24-hour incubation 
with 10 μM ARC-1042 in HeLa cells was (233 ± 58) μM, and the corres-
ponding average FI was (3100 ± 300) AU (Figure 10.B). As the FI in nucleoli 
of the chosen cell was more than 4800 AU, the particular concentration of the 
compound in nucleoli could be (in case of linear relationship between the con-
centration and FI) more than 360 μM, simultaneously the FI in the cytoplasm 
was approximately 2400 AU, pointing to 180 μM concentration. 
The cells were next incubated with 0.25…10 μM ARC-1042 for 24 h which 
led to 1.8…25-fold higher concentration of the compound in cells compared to 
that in the incubation solution (Figure 13.B). The shape of the graph could 
indicate increased proportion of directly penetrated (over endosomatically 
internalized) ARC-1042 as the concentration of incubation solution increases. 
This result is in concurrence with the general understanding of the dependence 
of uptake mechanism and extent on applied concentration of the arginine-rich 
compound (see section about CPPs in paragraph 2.2.2). Overall, the results of 
experiments with ARC-1042 demonstrated the possibility of regulation of the 
intracellular concentration of the probe in wide range, based on varying the 
concentration of the probe in the incubation medium and incubation time. The 
developed method could be also applied for analyses of intracellular con-
centration of various other inhibitors and probes. 
 
 
5.2. BIOLOGICAL EFFECT OF CELL-PENETRATING BILIGAND 
INHIBITORS OF PKS 
Recently, we showed that the in vitro potency and selectivity of PK inhibition 
can be remarkably increased by the biligand inhibitor approach (Lavogina et al. 
2010a), i.e., construction of conjugates that simultaneously occupy the binding 
sites of both the phospho-donor nucleotide and phospho-acceptor protein 
substrate of the PK. In this study, we developed two types of high-affinity and 
cell plasma membrane permeable biligand inhibitors: targeting either basophilic 
(e.g., PKA) or acidophilic kinases (e.g., CK2). Our aim was to establish the 
effectiveness of biligand inhibitors to suppress the phosphorylation of proteins 







5.2.1. Biligand Inhibitors of Basophilic PKs (PAPER I)  
Biligand inhibitors targeting basophilic protein kinases usually comprise positi-
vely charged amino acids in the peptide-mimicking moiety. Besides contri-
buting to binding affinity, arginines support the uptake of these compounds. 
HPLC-based analysis according to the method described in chapter 5.1.2 
demonstrated that previously developed ARC-type biligand inhibitors of baso-
philic PKs are intensively taken up by cells – a ten-fold higher intracellular con-
centration of the compound compared to their concentration in the incubation 
medium was achieved. In earlier studies it was demonstrated that myristoylated 
oligo-arginines possess even better cellular uptake than their non-acylated 
arginine-rich peptide counterparts (Lee and Tung 2010). In this regard, N-
myristylation of ARCs was used for further improvement of the cellular uptake 
















































Figure 14. Structure of ARC-1222, comprising a myristoyl group conjugated via the C-
terminal lysine residue. 
 
 
The biochemical affinity (Kd) of the developed compounds towards PKAc was 
determined with ARC-Lum-based assay described in Papers I and III using the 
selenophene-comprising probe ARC-1139 (Figure 1 in Paper I). The Kd of non-
myristoylated compound ARC-904 was approximately 10-fold lower (0.4 nM) 
compared to the myristoylated ARC-1222 (3.7 nM), both still remaining in the 
high-affinity range. Also, the acylated ARC bound to PKAc three-fold more 
tightly than H89 – a well-characterised commercially available ATP-competi-
tive inhibitor of PKAc (Kd = 10 nM) (Davies et al. 2000). 
HPLC-analyses demonstrated that the uptake of myristoylated ARC-1222 by 
the CHO cells was approximately 3-fold more efficient compared to its non-
myristoylated counterpart ARC-904. 1 h incubation with 10 μM ARC-1222 lead 
to 300 μM intracellular concentration. High affinity towards PKAc, high rate of 
cellular accumulation, and the great structural stability of ARCs in cellular 
milieu (Enkvist et al. 2006) pointed to the applicability of ARCs for regulation 
of intracellular protein phosphorylation balances. Several important cellular 
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signalling cascades are started by activation of PKA. For instance, CREB 
induces gene transcription after being phosphorylated at Ser133 by PKA or 
other PKs (Johannessen et al. 2004).  
We monitored how inhibitors of PKA affect phosphorylation of CREB 
(Figure 1) with an immunoblot-based protein phosphorylation assay. While H89 
and ARC-1222 (each at 10 μM) suppressed forskolin-induced phosphorylation 
of CREB, ARC-904 caused no significant change in CREB phosphorylation 
balance (Figure 15.A). The inhibitory potency of ARC-1222 was higher pro-
bably due to better cell membrane penetrative properties and despite the lower 
binding affinity towards PKAc compared to ARC-904. More efficient inhibition 
of the cAMP/PKA pathway by H89 relative to its three fold lower affinity 
compared to ARCs may be (partially) due to its better internalization into cells 










































no inhibitor H89 ARC-1222 ARC-904
A B
 
Figure 15. A) The effect of H89, ARC-1222, and ARC-904 on the phosphorylation of 
CREB in CHO cells. Cells were treated with 10 μM compound for 1 h, and then 
stimulated with 10 μM forskolin for 30 min. The data concerning inhibitor-treated cells 
was normalised relative to the ratio of integrated intensities of the bands of phospho-
CREB and α-tubulin of non-treated cells (n = 3, average ± SDM). B) Cell viability 
determined by trypan blue exclusion test. The CHO cells were incubated with 1… 




To test the cytotoxic effect of the compound, cell viability was determined in 
assays with Trypan Blue (Figure 15.B). After 1 h incubation with ARC-1222 at 
1…10 μM, the viability of the cells varied from 100% to 80%. At 20 μM ARC-
1222 the viability was substantially reduced (<50% of the control). The effect of 
myristoylated compound on the cell viability at high concentration might be the 
result of membrane destruction (Brock 2014; Shai et al. 2006). However, the 
relatively high cell viability over 1…10 μM ARC-1222 shows that the change 
in the luciferase activity and CREB phosphorylation is likely to be caused by 
the inhibition of PKAc and not by cytotoxicity of the compound. 
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As demonstrated in the present study, the improvement of cellular inhibitory 
potency of ARCs targeting basophilic PKs could be achieved with simple 
structural modification of the conjugates, N-myristoylation of ARCs. This result 
points to the importance of further research on structural modifications of ARCs 
that could lead to their better intracellular targeting, improved availability by 
nuclear PKs, and inhibition of PKs. 
 
 
5.2.1. Biligand Inhibitors of CK2 (Paper II and IV) 
As for other PKs, the development of inhibitors of CK2 has been mainly 
focused to nucleotide-competitive inhibitors. ATP-competitive CX-4945, the 
only CK2 inhibitor that has reached clinical trials, is the most successful 
example. Development of substrate protein competitive or biligand inhibitors of 
CK2 has not been popular as the acidophilic nature of CK2 dictates the need for 
negatively charged peptide sequences, making these compounds poorly plasma 
membrane permeable. Nevertheless, we aimed to develop cell plasma mem-
brane permeable biligand inhibitors as they are potentially more selective and 
potent compared to ATP-competitive inhibitors.  
 
 
5.2.2.1. Acetoxymethyl Ester of Tetrabromobenzimidazole-Peptoid 
Conjugate for Inhibition of CK2 in Living Cells 
We had previously developed selective high-affinity  (Kd <1 nM) biligand inhi-
bitors (ARCs) for CK2 that were suitable for biochemical studies, but due to 
poor proteolytic stability and plasma membrane permeability, the compounds 
were not suitable for cellular studies (Ekambaram et al. 2014; Enkvist et al. 
2012). Here, the structure of CK2-targeted ARCs was modified for the 
application in live cells. The oligo-aspartate moiety present in previously 
reported structures (Vahter et al. 2017; Enkvist et al. 2012) was replaced with 
the corresponding carboxylate-rich peptoid chain comprising N-carboxymethyl-
glycine (iminodiacetic acid, Ida) residues. Proteolytically stable achiral oli-
goanionic peptoid conjugates of 4,5,6,7-tetrabromo-1H-benzimidazole (TBBz) 
were constructed and ARC-1842 [Kd,CK2 = (8.7 ± 0.7) nM] was chosen for 
further studies on cells. The oligocarboxylic acid part of the inhibitor was mo-
dified for increasing its stability in biofluids (Miller et al. 1995) and for 
enabling its loading into cell in the form of per-acetoxymethyl (AM) ester 




Figure 16. Schematic presentation of cellular uptake of per-esterified compound ARC-
1859 that is hydrolysed to ARC-1842 by esterases in cells. 
 
 
The inhibition potency of CK2 inhibitors was investigated in MIA PaCa-2 cells. 
Western blot analysis was performed for determination of the phosphorylation 
status of two CK2 substrates: Cdc37 and NFκB. Treatment of cells with 10 μM 
ARC-1859 (AM-form of ARC-1842, Figure 17.A) decreased the phospho-
rylation level of the substrates by the same extent as the control inhibitor CX-
4945 at the same concentration. Controversially, ARC-1842 did not have signi-
ficant influence on the phosphorylation balance as expected because of poor 
uptake of the non-esterified conjugate. 
As inhibition of CK2 in cells leads to activation of CASP3 and thereafter to 
apoptosis [Figure 2.B (Turowec et al. 2013; Duncan et al. 2011)], the effect of 
CK2 inhibitors on the viability of HeLa and MIA PaCa-2 cells was studied. 
ARC-1859 showed concentration-dependent reduction of viability for both 
types of cells (Figure 17.B, Supporting Information Figure S5 in Paper II). 
There were about 60% of viable cells after 24 h treatment with 10 μM ARC-
1859 and 50% after 48 h treatment. On the contrary, no effect with ARC-1842 
was observed in the course of the experiments (Figure 17.B, Supporting Infor-
mation Figure S5 in Paper II). The effect of CX-4945 on cell viability was 
similar to that of ARC-1859 in HeLa cells. TBBz was used as the reference 
compound in HeLa cell line that at 10 μM concentration caused about 20% of 
loss of viability after 24 h incubation and 50% after 48 h incubation (Figure 
17.B, Figure 5.B in Paper II). Although TBBz has more than 70-fold lower 
affinity towards CK2 compared to the conjugate of TBBz and oligoanionic 
peptoid (Table 1 in Paper II), it induces cellular death to a similar extent. The 
latter phenomenon could be explained by nonspecific interactions of TBBz with 





Figure 17. A) Western blot analysis of whole lysates from MIA PaCa-2 cells. Control 
(C) experiment refers to cells treated with vehicle (0.1% DMSO v/v). -actin 
measurement was used as the control for equal loading. Values beneath protein bands 
refer to the results of densitometric analysis of integrated band intensities expressed in 
percentage values. Cells were incubated with 10 µM ARC-1842, ARC-1859, or CX-
4945 for 5 h. B) Cytotoxic effect of ARC-1842 (blue ●), ARC-1859 (red ■), CX-4945 
(green ▼) or TBBz (purple □) in HeLa cells (trypan blue test). Control experiment (c = 
0) refers to cells treated with vehicle (DMSO and Pluronic F-127). HeLa cells were 
treated for 24 h with increasing concentrations of compounds, as indicated. The 
reported values represent the means ± SD from three parallel experiments. 
 
 
To the best of our knowledge, this is the first study of the application of AM 
ester loading technique to enhance the bioavailability of compounds comprising 
an oligoanionic peptoid backbone. This technique also represents a general 
approach for designing cell-permeable prodrugs of highly potent and selective 
biligand inhibitors of CK2. 
 
 
5.2.2.2. Construction of Selective and  
Cell-Penetrating Biligand Inhibitors of CK2 
Although TBBz and its biligand conjugates revealed good inhibitory potency, 
the moiety also accompanies several disadvantages (selectivity, solubility, and 
non-specific binding issues). Thus, our next aim was to change the fragment 
targeting the nucleotide binding pocket of CK2 to a more promising hetero-
aromatic moiety. 4-(2-amino-1,3-thiazol-5-yl)benzoic acid (ATB) moiety pos-
sesses several outstanding properties for the construction of biligand inhibitors. 
First, it is less hydrophobic compared to TBBz. Second, it has remarkable 
affinity towards CK2 and its cellular activity has been demonstrated (Hou et al. 
2012). Third, the moiety possesses good fluorescence properties, which enables 
its sensitive quantification with HPLC (Figure S. 1 in Paper IV). 
Length of the linker connecting ATB moiety to the peptoid composed of N-
carboxymethylglycine (iminodiacetic acid, Ida) residues was optimized for 
gaining high affinity of the inhibitor. Based on the affinity analysis (Table 1, 
compounds 1…6 in Paper IV) the linker comprising succinic acid and 12-
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aminododecanoic acid residues connected via N-carboxymethylated amide bond 
was chosen for further studies. As for other previously reported biligand 
inhibitors of CK2 (Viht et al. 2015), binding affinity increased with the number 
of Ida-residues in the peptoid chain. Among the constructed inhibitors, con-
jugate with 5 Ida residues reached the lowest Kd value of 40 pM. However, 
taking into account molecular weight, structural complexity, and binding 
affinity, the compound comprising 3 Ida residues [ARC-772, Kd,CK2 = (0.3 ± 
0.1) nM, Figure 18] was considered structurally more promising for cellular 



























Figure 18. Structure of ARC-772. 
 
 
The inhibition selectivity of ARC-772 was tested in a commercial panel of 140 
PKs to discover the off-targets of the inhibitor (Figure 19, Table 2 in Paper IV). 
ARC-772 revealed Gini coefficient of 0.752 and hit rate of 0.05, which 
highlighted the good selectivity of the compound. The hit rate demonstrated that 
among the tested PKs only 5% (including CK2, 3 PKs of the DYRK family, 













































































5.2.2.2.1. Intracellular Delivery 
Similarly to our previously developed biligand CK2 inhibitor ARC-1842 
(described in Paper II and chapter 5.2.2.1), ARC-772 possessed properties like 
good affinity and selectivity, accompanied with low cellular accumulation. 
Although the per-esterification technique applied in Paper II supported the 
plasma membrane penetration of the negatively charged compound, it was in 
our interest to compare the efficiency of other technologies for transport of 
ARC-772 into cells. Five different technologies were tested for the delivery of 
ARC-772 into cells (Figure 20): conjugation of the ligand with folic acid 
(Sudimack and Lee 2000), RPARPAR (Simón-Gracia et al. 2016), or (L-Arg)9 
moiety (Trabulo et al. 2010); masking the negatively charged carboxyl groups 
as esters (Viht et al. 2015); and encapsulating ARC-772 into micelles of the 
transfection reagent TurboFect. In order to enable attachment of various 
transporters to ARC-772, a sulfhydryl group was added to the C-terminus of the 
peptoid [Scheme S. 1.E, compound 11 (ARC-772-SH) in Paper IV]. Two of the 
applied delivering techniques have been used for specific targeting of cancerous 
cells; the uptake mechanisms included receptor-mediated endocytosis. First, 
folate receptor-mediated delivery of the folate conjugated compound (ARC-
778) and, secondly, neuropilin-1 receptor (NRP-1) mediated delivery of the 










The efficiency of uptake techniques was compared by determining the intra-
cellular concentration of the compound after 12 h incubation with HeLa cells. 
We applied the HPLC method described in chapter 5.1.2, with the difference of 
detecting fluorescence intensity derived from the ATB moiety. The limit of 
quantification (LoQ) of the RP-HPLC-FL methodology was 5.1 fmol. 
ARC-772 without any transporter penetrated the cell plasma membrane 
poorly, leading to low micromolar intracellular concentration (Figure 21). 
Despite the overexpression of folate receptors (Sudimack and Lee 2000; Paulos 
et al. 2004; Saul et al. 2003) as well as NRP-1 receptors (Bagri et al. 2009; 
Pellet-Many et al. 2008) in cancerous cells, these receptor-mediated transport 
techniques did not enhance the uptake efficiency of the compound. Similarly, 
no significant uptake enhancement was gained with conjugation of transport 
peptide (L-Arg)9 to ARC-772-SH (code of conjugate:ARC-783). The latter 
could be explained by both, inefficient endosomatic uptake (Ma et al. 2012) and 
masking of positively charged guanidinium groups of (L-Arg)9 with the 
negatively charged carboxyl groups of ARC-772-SH. Commercially available 
transfection reagent TurboFect is mostly used for introducing nucleic acids into 
eukaryotic cells. Despite the numerous positive charges of the transfection 
reagent suitable for forming charge-charge interactions with ARC-772, it did 




Figure 21. Comparison of the efficiency of different internalization methods on basis of 
the intracellular concentration of ARC-772 in HeLa cells (n = 3) as determined with 
HPLC analysis. Incubation solution containing the compound at 5 μM or 1 μM con-




Remarkably efficient uptake of the inhibitor ARC-772 was achieved if it was 
used in the form of per-acetoxymethyl ester prodrug of the compound, ARC-
775. The treatment of cells with 5 μM solution of ARC-775 led to more than 
100 μM intracellular concentration of ARC-772. Inside cellular milieu, the ester 
groups of ARC-775 are hydrolysed by esterases within less than an hour. 
Hydrolysed compound is thereafter trapped in cells and possesses full activity 
for its interaction with CK2 (Viht et al. 2015). 
We explain the modest uptake efficiency of the tested techniques [con-
jugation of folate, RPARPAR or (L-Arg)9, or micellization with TurboFect] 
with the following hypothesis. All of these technologies used different types of 
endocytosis mechanisms for uptake and the bonds between inhibitor and trans-
port system or receptor and transport system were destabilised in the acidic 
environment of the endosome (pH 5.5…6.5, depending on the development 
stage of the endosome). First, in case of charge-charge interactions [e.g., 
between TurboFect and ARC-772, or folate and RPARPAR with corresponding 
receptors] the acidic environment affected the binding affinity. Second, when a 
disulphide bridge was applied to connect transport system and inhibitor, the 
acidic environment enhanced the enzymatic reduction of disulphide bond 
(Arunachalam et al. 2000). Once the bond between the transporter and inhibitor 
is destabilised, it is highly likely, that the negatively charged ARC-772 (or 
ARC-772-SH) does not effectively escape to the cytosol. In case of folate and 
RPARPAR technologies the limiting factor is also the recycling efficiency and 
the number of the corresponding receptors. 
The cellular accumulation of per-esterified compound ARC-775 was further 
tested upon 1 h, 5 h, and 12 h incubation period (Figure 22). Approximately 20-
fold increase of concentration of ARC-772 was recorded in cells, compared to 
concentration of the prodrug ARC-775 in incubation solution (tested at extra-
cellular concentrations of 0.5 μM, 1.0 μM, and 5.0 μM; 5 h incubation). The 
concentration in cells was somewhat reduced at 12 h time point that may point 
to activation of apoptotic or other processes leading to cell death and export of 
ARC-772 from cells. Moreover, as the difference in intracellular concentration 
after 5 h and 12 h incubation with 5.0 μM ARC-775 was not significant, ARC-







































































































Figure 22. Intracellular concentration of ARC-772 in HeLa cells after treatment of the 
cells with various concentrations of ARC-775 for 1 h, 5 h, or 12 h, n = 3. 
 
5.2.2.2.2. Regulation of Cell's Physiology 
In case of negatively charged ARCs the prodrug approach leads to very high 
intracellular concentration as after hydrolysis of ester groups the drug is trapped 
in cells. The functionality of ARC-772 as an inhibitor was demonstrated in three 
types of assay: determination of the phosphorylation level of a CK2 substrate 
protein Cdc37; determination of activity of CASP3 (by monitoring the cleavage 
of FRET probe GFP-Asp-Glu-Val-Asp-RFP); and measurement of the effect on 
platelet aggregation (Figure 23). 
 
 
Figure 23. Upon penetration of cell plasma membrane, the prodrug ARC-775 is 
modified by esterases into its active form ARC-772. The efficiency of the inhibitor in 
the cellular milieu is demonstrated by three assays (written in bold). 
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Inhibition of Phosphorylation of Substrate-Protein Cdc37 
CK2 mediated phosphorylation of kinase-specific co-chaperone Cdc37 is 
critical for binding of PKs and activity of chaperone Hsp90 [Figure 2.A 
(MacLean and Picard 2003)]. Active Cdc37 assists the correct folding and 
functions of many signalling PKs. Cdc37 also plays a role in mediating the 
development of cancer by stabilizing the compromised structures of oncogenic 
kinases (Pearl 2005; Gray et al. 2008). Accordingly, inhibition of CK2 may 
result in numerous benefits. 
We tested the efficiency of developed prodrug ARC-775 and compared its 
effect with the efficiency of well-known control compound, CK2 inhibitor CX-
4945. Treatment of cancerous HeLa cells with ARC-775 or CX-4945 resulted in 
efficient inhibition of CK2-catalyzed phosphorylation of Cdc37 at Ser13. The 
average pCdc37/Cdc37 ratio (compared to that of control) of ARC-775 (5 μM) 
treated cells was (44 ± 8)% after 5 h and (36 ± 7)% after 12 h incubation, CX-
4945 revealed phosphorylation level of (72 ± 10)% after 5 h and (55 ± 8)% after 
12 h incubation (Figure 24). It was recently shown that even in case of full 
exclusion of CK2 activity in cells does not lead to full disappearance of pCdc37 
from cells (Franchin et al. 2017b), meaning that other PKs can to some extent 
replace CK2 as phosphorylation catalysts. In conclusion, the results support the 
use of oligoanionic biligand inhibitors in the form of per-esterified prodrug for 































Figure 24. Average pCdc37/Cdc37 ratio results of HeLa cells (n = 3). Control is the 
pCdc37/Cdc37 ratio in untreated cells. 
 
 
Affecting the Activity of CASP3 
Activation of CASP3 induces apoptosis, thus the former process can be used to 
characterise molecular regulators of programmed cell death. The role of cas-
pases in apoptosis is regulated by the CK2-dependent phosphorylation in many 
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ways (Turowec et al. 2013; Duncan et al. 2011). First, phosphorylated target 
proteins are not cleaved by CASP3. Second, phosphorylated procaspase-3 is 
protected from cleavage by CASP8 and CASP9, which, in turn, prevents the 
activation of CASP3. Third, the phosphorylation of CASP3 by CK2 directly 
inactivates it (Figure 2.B). Therefore we studied the effect of three inhibitors on 
activity of CASP3. While CX-4945 and ARC-775, probably, affect the activity 
of CASP3 as CK2 inhibitors, effect of Staurosporine on CASP3 is complex as it 
inhibits many PKs simultaneously (Belmokhtar et al. 2001; Karaman et al. 
2008).  
The activation of CASP3 upon treatment of cells with PK inhibitors is 
clearly seen in case of both, cancerous HeLa cells and noncancerous CHO cells. 
However, the kinetic profiles were substantially dependent on type of the cell 
line and origin of the tested compound. The maximal activity of CASP3 was 
achieved upon 12 h treatment of HeLa cells with ARC-775, whereas CX-4945 
and Staurosporine showed faster effect – it took 8 h and 4 h to achieve maximal 
activity of CASP3, accordingly (Figure 25.A). In case of noncancerous CHO 
cells, the activation kinetics of CASP3 was substantially slower for all com-
pounds (Figure 25.B). As it has been reported previously, the time-scale of 
induction of apoptosis for Staurosporine is dependent on the particular apoptotic 
pathway – the caspase dependent pathway was quicker (3 h), and caspase 
independent pathway slower (>12 h) (Belmokhtar et al. 2001). In case of CK2 
inhibitors CX-4945 and ARC-775, the apoptosis should be induced by caspase-
dependent pathway, nevertheless the activation of CASP3 was delayed. The 
non-compliance for ARC-775 could be partly explained by the extra time 
needed for the de-esterification of the prodrug [up to an hour (Viht et al. 2015)], 



















































Figure 25. Kinetics of CASP3 activity during treatment with ARC-775 (5 μM), CX-




The comparison of EC50 values of caspase activation (Table 2) for cancerous 
HeLa cells and noncancerous CHO cells confirms the previous knowledge: the 
viability of cancerous cells is more reliant on the activity of CK2 than that of 
non-cancerous cells (Siddiqui-Jain et al. 2010; Ruzzene and Pinna 2010). Thus 
the effect of ARC-775 on CASP3 activation in cancerous HeLa cells is more 
conspicuous than that of CX-4945 and Staurosporine. The ratio in the EC50 
values found for these compounds in HeLa and CHO cells was 53-, 5.5-, and 3-
fold, respectively. These results support further investigation of ARC-775 as a 
cancer cell-selective prodrug. 
 
 
Table 2. EC50 values determined from the dose–response curves of ARC-775, CX-
4945, and staurosporine for HeLa and CHO cells 
 
Cell line Compound (EC50 ± SD)/µM 
CHO ARC-775 ~16 
 CX-4945 36 ± 2 
 Staurosporine 0.09 ± 0.01  
HeLa ARC-775 0.3 ± 0.1 
 CX-4945 6.5 ± 1.1 
 Staurosporine 0.03 ± 0.01 
 
 
Inhibition of Aggregation of Platelets 
Previous findings indicate that CK2 regulates multiple interaction mechanisms 
that mediate the activity of platelets (Nakanishi et al. 2008; Ryu and Kim 2013; 
Ampofo et al. 2015; Hoyt et al. 1994). Therefore, inhibition of CK2 may contri-
bute to the future treatment of diseases which accompany thrombosis. Here, the 
effect of CK2 inhibitors and Forskolin on the ADP-induced aggregation of hu-
man platelets was studied. CK2 inhibitors lower the expression of P-selectin, 
inhibition of glycoprotein IIb/IIIa (Ampofo et al. 2015) and downstream targets 
of the PI 3-kinase pathways (Figure 2.C). Forskolin, on the other hand, inhibits 
platelet aggregation by activating adenylyl cyclase, production of cAMP, and, 
in consequence, activation of PKA (Kariya et al. 1985; Insel et al. 1982).  
In our experiments platelets were pre-treated with compounds of interest for 
30 min or 60 min; thereafter, aggregation was initiated by the addition of ADP. 
Choice of the compound initiating the aggregation process for studying the 
effect of was made based on the knowledge that activation of platelets by ADP 
results in inhibition of the PKA pathway and utilization of the intrinsically 
active CK2-catalyzed pathways. The optimal concentration of ADP that con-
sistently induced significant aggregation and sufficient measurement window 
with high signal to noise ratio was 25 μM (Figure 8.A in paper IV). The addi-
tion of ADP induced aggregation quickly, reaching the maximal effect within 
5…6 min. 
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The results of experiments with human platelets (Figure 26) demonstrated 
good efficiency of ARC-775 in inhibition of ADP-induced platelet aggregation. 
While the platelets pre-treated for 30 min with ARC-775 resulted in (16 ± 3)% 
of maximum aggregation (MA), the platelets pre-treated for 60 min de-
monstrated even negative aggregation percent [MA = (-56 ± 11)%], pointing to 
decrease from the basal level of aggregation. The improved influence of ARC-
775 over time could be clearly related to the effect of increased proportion of 
de-esterified prodrug. Another prodrug of a biligand inhibitor (ARC-1859) did 
not show significantly different results for 30 min and 60 min incubation period. 
Despite lower affinity of the de-esterified form of ARC-1859 (Kd,ARC-1842-CK2 = 
8.7 nM) compared to ARC-772 (Kd,ARC-772-CK2 = 0.3 nM) as well as to CX-4945 
[Kd,CX-4945-CK2 = 0.56 nM (Enkvist et al. 2012)], ARC-1859 and CX-4945 
revealed comparable efficiency for inhibition of aggregation. Pre-treatment of 
the platelets with Forskolin resulted in significant suppression of aggregation. 
Moreover, the effect of Forskolin was more pronounced after 30 min pre-incu-
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Figure 26. ADP-induced aggregation of platelets. The platelets were pre-incubated for 
30 min or 60 min with a compound of interest (COI): ARC-775, ARC-1859, CX-4945, 
or Forskolin (n = 3). The aggregation of platelets was initiated with 25 μM ADP. * p < 
0.05 compared to active platelets (platelets + ADP). 
 
 
To sum up, three different assays were used to demonstrate the capability of 
ARC-772 prodrug ARC-775 to regulate the activity of CK2 in cells. First, 
inhibition of CK2 with ARC-772 resulted in lowered proportion of phospho-
rylated Cdc37 in HeLa cell lysate at similar or slightly lower level than in the 
presence of CX-4945, the first CK2 inhibitor in clinical trials. This change in 
phosphorylation balance could affect the proper folding of client proteins of 
Cdc37 and thus influence many processes in cells. Next, it was studied how 
inhibition of CK2 regulates the activity of CASP3. A distinctive specificity 
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between cancerous HeLa cells and non-cancer CHO cells was achieved with 
ARC-775. Despite similar CK2-binding affinities of ARC-772 and CX-4945, 
ARC-775 possessed 20-fold lower EC50 value for CASP3 activation in HeLa 
cells that may be caused by trapping ARC-772 at high concentration in cells. 
Finally, it was demonstrated for the first time that effective suppression of plate-
let aggregation is possible by their treatment with prodrugs of biligand inhibi-
tors of CK2.  
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6. CONCLUSIONS 
The present thesis focussed on the development of methods for characterising of 
PK inhibitors in biochemical assays and on the design and cellular application 
of biligand inhibitors of basophilic and acidophilic PKs for regulation of cell 
physiology. The main results of the current thesis can be summarised as fol-
lows. 
 The methodology of applying a non-metal photoluminescent protein-
binding-responsive probe [ARC-Lum(Fluo) probe] for determination of 
dissociation constants of competitive inhibitors of PKs was worked out. 
High affinity (Kd = 20 pM) and low background signal of the free probe 
supported the determination of dissociation constants of tight-binding as well 
as low affinity inhibitors. The lowest resolvable Kd value (Kd = 60 fM) was 
~300-fold lower than that value reported for commercially available 
LanthaScreen™ Eu Kinase Binding Assay. 
 A graphical presentation of the linearized Cheng-Prusoff equation was 
introduced and multiple possibilities for its application in determining 
affinities of PK inhibitors were presented. Quality and economic aspects of 
performing the measurements were disclosed, which together with the 
graphical presentation aids the decision making upon choosing the assay 
conditions, calculation of LoKd values, and convenient conversion of IC50 
values to Kd values. 
 An HPLC based method for determination of intracellular concentration of 
ARCs with a fluorescent label (probes) and without it (inhibitors) was 
developed. It was demonstrated, that by regulating the extracellular con-
centration and incubation time, it was possible to gain very high (~350 μM), 
but also low (~600 nM) intracellular concentration of the compounds. Com-
bining fluorescence microscopy analysis with HPLC analysis enabled the 
prediction of the concentration of probes in particular cellular compartments. 
 The improvement of cellular uptake efficiency of biligand inhibitors (ARCs) 
targeting basophilic PKs was achieved with N-myristoylation of the con-
jugates. Good PKAc inhibitory properties were demonstrated without 
causing cytotoxic effect to the cell. 
 The acetoxymethyl ester loading technique was applied to enhance the bio-
availability of ARCs targeting acidophilic PKs. The method resulted in 
significantly higher cellular uptake compared to other techniques (con-
jugation of folate, RPARPAR, Arg9, or applying transfection reagent 
TurboFect). 
 High selectivity and affinity of the developed biligand inhibitor ARC-772 
towards CK2 led to discriminating activation of apoptosis of cancerous 
HeLa cells compared to inhibitors CX-4945 and Staurosporine. 
 Effective suppression of ADP-induced platelet aggregation upon their treat-
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SUMMARY IN ESTONIAN 
ARC-inhibiitorid: usaldusväärsetest biokeemilistest meetoditest 
rakkude füsioloogia reguleerimiseni 
Inimrakk on keeruline süsteem, mis koosneb paljudest molekulidest ning ran-
gelt reguleeritud molekulidevahelisest kommunikatsioonist. Ühed osalised raku 
elutegevuses on proteiinkinaaside (PKde) perekonna liikmed, mis koosneb ligi-
kaudu 500 liikmest (Manning et al. 2002). PKde rolliks on katalüüsida fosfo-
rüülrühma ülekannet ATPlt sihtvalgule. Väike muudatus (fosforüülimine) siht-
valgu keemilises struktuuris mõjutab oluliselt sihtvalkude aktiivsust ning see-
tõttu ka raku elutegevuseks vajalikke protsesse.  
Kuigi esimene PK avastati juba 1954. aastal (Burnett and Kennedy 1954), 
toimus PKde uurimises hüppeline areng alles 30 aastat hiljem. Aastate jooksul 
on kindlaks tehtud paljude PKde signaalradade eripärad ja ka PKde roll mitmete 
haiguste (nt neurodegeneratiivsete haiguste, vähkkasvajate, diabeedi, südame-
veresoonkonna haiguste) tekkes. Tänaseks on vähiravimina USA terapeutiliste 
kaupade regulatsiooni (NDA) poolt kinnitatud üle 35 väikese molekulmassiga 
ühendi (Wu et al. 2015; Fabbro et al. 2015; Sharma et al. 2016; Rask-Andersen 
et al. 2014b). PKdega seotud arendusvaldkondades on oluline osakaal ka eri-
nevatel biokeemilistel meetoditel nii uute ravimikandidaatide analüüsimiseks, 
PKde signaalradade uurimiseks kui ka PKde osaluse tuvastamiseks erinevate 
haiguste tekkes. 
Käesoleva töö esimeses osas keskenduti analüüsimeetodite ning teises osas 
inhibiitorite arendusele ning rakendamisele. Mõlemal puhul kasutati biligand-
seid ühendeid, ARCe. Biligandne inhibiitor seostub kinaasi kahe substraadi-
taskuga korraga, mistõttu saavutatakse kõrge seostumisafiinsus ja selektiivsus 
sihtvalgu suhtes. 
Esmalt analüüsiti unikaalsete fotoluminestsentsomadustega ARC-Lum(Fluo) 
sondi võimekust PK inhibiitorite dissotsiatsioonikonstantide (Kd) määramisel. 
Enamik inhibiitorite kiirsõeluuringu meetoditest kasutab antikeha ja fluorest-
sentsmarkeri kombinatsiooni. Antud töös kasutati vaid üht sondi, tänu millele 
on meetod võrreldes paljude teistega lihtsam, odavam ja täpsem.  Leiti, et mee-
todi Kd määramispiir on 60 fM, mis on ligikaudu 300 korda madalam võrreldes 
senini enimkasutatud LanthaScreen™ Eu meetodiga. Meetodi tundlikkus on 
saavutatud peamiselt tänu uue meetodi kõrgele signaal-müra suhtele ja sondi 
afiinsusele (20 pM). Meetodi optimeerimisel pandi rõhku ka majanduslikele 
aspektidele. Töös tutvustati ka veebirakendust, mis toetab sobilike analüüsi-
tingimuste valimist, mille juures on võimalik inhibiitorite seostumiskonstante 
määrata täpselt ning madalate kuludega. 
Teisena arendati vedelikkromatograafiline meetod ARC-inhibiitorite ja -son-
dide rakusisese stabiilsuse ning kontsentratsiooni määramiseks. Näidati, et 
ühendite rakusisest kontsentratsiooni on võimalik reguleerida laias vahemikus 
(600 nM kuni 350 μM), varieerides rakkudele lisatud ainete kontsentratsioone 
ning inkubatsiooniaega. Samuti demonstreeriti, et basofiilseid PKsid sihtivad 
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ARC-ühendid sisenevad rakkudesse kiiresti (juba 10 min saavutatakse 30 μM 
kontsentratsioon) ning ained on rakkudes stabiilsed vähemalt 150 h jooksul. 
Selline paindlikkus võimaldab kasutada ARC-inhibiitoreid nii kiiretes sõel-
uuringutes kui ka katsetes, kus on vajalik jälgida inhibiitori mõju raku signaal-
radadele pikema aja jooksul. Kontsentratsiooni peenhäälestamine võimaldab 
vähendada rakkude ülekoormamist inhibiitoritega ning sealjuures minimiseerida 
ainete  mittespetsiifilist seostumist valkudega. 
Töö teine osa keskendus selliste biligandsete inhibiitorite arendusele, mis 
seonduvad PKde CK2 või PKA aktiivtsentrisse. PKA on alates selle avasta-
misest olnud enim uuritud PK ning seda kinaasi seostatakse erinevate südame-
haiguste ja kasvajatega. Samuti on tuvastatud, et erinevate vähkkasvajatega 
patsientide veres on PKA kontsentratsioon kõrgem, mis teeb PKA ka oluliseks 
vähktõve biomarkeriks. Töögrupis oli varasemalt disainitud afiinne biligandne 
PKA inhibiitor ARC-904. Ühend sisenes rakkudesse väga efektiivselt (inku-
beerides 1 h 10 µM ARC-904ga saavutati 100 µM rakusisene kontsentratsioon), 
kuid ei inhibeerinud PKAd raku tuumas vaatamata aine kõrgele kontsentrat-
sioonile ning afiinsusele. Tõstmaks rakkudesse sisenemise efektiivsust, konju-
geeriti ARC-904ga müristoüülrühm. Sellise struktuurilise muudatuse toel saa-
vutati kolmekordne inhibiitori kontsentratsiooni tõus. Kuigi müristoüülitud 
ARC-1222 seostus PKAle ligi 10 korda madalama afiinsusega kui ARC-904 (Kd 
vastavalt 3,7 nM ja 0,4 nM), inhibeeris ARC-1222 PKAd rakkudes märgatavalt 
paremini. ARC-1222 inhibeerimisvõimekus oli võrreldes kommertsiaalse ATP-
konkurentse inhibiitoriga H89 [Kd = 10 nM, (Davies et al. 2000)] ligikaudu kaks 
korda parem. 
Teise kinaasina pakkus meile huvi CK2, mis katalüüsib hinnanguliselt ligi 
20% kõigist valkude fosforüülimistest imetajate rakkudes. CK2 suurenenud 
aktiivsust on seostatud erinevate haigustega (sh vähktõve erinevad liigid ja 
tromboos), kusjuures arvatakse, et vähirakud vajavad oma elutegevuseks CK2 
kõrget aktiivsust. Käesoleva töö käigus arendati seeria biligandseid CK2 in-
hibiitoreid. Parimale inhibiitorile oli omane nii kõrge afiinsus (40 pM) kui ka 
hea selektiivsus CK2 suhtes. CK2 sihtivate biligandsete inhibiitorite struktuu-
riliseks eripäraks on nende negatiivselt laetud peptiidne fragment, mis pärsib 
ainete suutlikkust läbida rakkude plasmamembraani. Töös katsetati erinevaid 
tehnoloogiaid ainete rakku sisenemise võimekuse tõstmiseks ning kõige tõhusa-
maks lahenduseks osutus karboksüülhapete esterdamine. Rakkudes estrid 
hüdrolüüsitakse, mille tulemusena avaldub inhibiitori funktsionaalsus CK2 
suhtes. Ühendi ARC-772 (Kd = 0,3 nM) tõhusust CK2 inhibeerimisel illustreeris 
selektiivne apoptoosi aktiveerimine vähirakkudes juba aine mikromolaarsete 
kontsentratsioonide juures. Samadel tingimustel oli aine mõju normaalsetele 
rakkudele tühine. Vähirakkude selektiivsust tervete rakkude suhtes iseloomustas 
ARC-772 estri ligikaudu 50-kordne erinevus EC50 väärtustes. Kliinilistes katse-
tustes oleva ATP-konkurentse CK2 inhibiitori CX-4945 (Kd = 0,4 nM) puhul oli 
vastav erinevus vaid 5,5-kordne. 
Kuna CK2 mängib olulist rolli ka tromboosi tekkes, testiti ARC-772 efek-
tiivsust vereliistakute agregatsiooni vähendamisel. Saadud tulemused näitasid, 
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et ARC-772 vähendas võrreldes CX-4945ga märgatavalt efektiivsemalt ATP 
lisamisega esile kutsutud vereliistakute agregatsiooni. 
Antud töö raames arendatud meetodid võimaldavad nii inhibiitorite afiinsus-
konstantide täpsemat määramist kui ka ainete kontsentratsiooni määramist 
rakkudes. Uurimistöös arendatud selektiivsed, afiinsed ning hea raku plasma-
membraani läbimisvõimega biligandsed inhibiitorid reguleerisid efektiivselt 
CK2 ja PKAga seotud signaalradasid. Doktoritöö tulemused toetavad biligand-
sete inhibiitorite rakendamist ravimiarenduses, haiguste diagnostikas ning bio-
meditsiinilistes uuringutes.  
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